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ABSTRACT 
Pedro Nicolas Pozo: Determining The Cellular and Molecular Consequences of Naturally-
Occurring and Engineered Mutations in The Cell Cycle Gene CDT1 
(Under the direction of Jeanette Gowen Cook) 
 
 
 The cell division cycle is composed of two major events; 1. DNA replication (S phase) 
and 2. chromosome segregation (M phase). In addition, gap phases exist to prepare cells for the 
duplication of their entire genome (G1 phase) and to check that the genome has been faithfully 
duplicated before cell division (G2 phase). This entire process involves many steps each 
governed by a set of molecular mechanisms that allow cells to transition from one cell cycle 
phase to the next. How these mechanisms are arranged and linked to intra- and extracellular cues 
for timely and coordinated cell division is a topic of great interest in the field. In this work, we 
focus on a critical step for cell cycle progression, known as origin licensing, with emphasis on 
elucidating the molecular function of Cdt1. The Cdt1 protein is highly conserved in metazoans 
and its role is essential for origin licensing, yet the mechanism of Cdt1 function is still 
incompletely understood.  
 We examined a collection of rare Cdt1 variants that cause a form of primordial dwarfism 
(Meier-Gorlin syndrome) plus one hypomorphic Drosophila allele to shed light on Cdt1 
function. Three hypomorphic variants load MCM less efficiently than WT Cdt1, and their lower 
activity correlates with impaired MCM binding. A structural homology model of the human 
Cdt1-MCM complex position the altered Cdt1 residues at two distinct interfaces rather than the 
previously described single MCM interaction domain. Surprisingly, one dwarfism allele (Cdt1-
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A66T) is more active than WT Cdt1. This hypermorphic variant binds both Cyclin A and SCFSkp2 
poorly relative to WT Cdt1. Detailed quantitative live cell imaging analysis demonstrated no 
change in stability of this variant however. Instead, we propose that Cyclin A/CDK inhibits Cdt1 
licensing function independently of the creation of the SCFSkp2 phosphodegron.  
 Together, these findings identify key Cdt1 interactions required for both efficient origin 
licensing and tight Cdt1 regulation to ensure normal cell proliferation and genome stability. In 
addition, we present here recent advances in elucidating Cdt1 molecular functions in origin 
licensing as well as describe the current understanding of human Cdt1 regulation.  
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CHAPTER 1: INTRODUCTION1 
 
Origin licensing, the loading of replicative DNA helicases onto origin DNA, is the first 
committed step of DNA replication and is essential for cell proliferation. Numerous control 
mechanisms in eukaryotic cells regulate both origin licensing and subsequent replication 
initiation to ensure complete and precise genome duplication (Li and Jin, 2010; Masai et al., 
2010; Blow et al., 2011; Truong and Wu, 2011; Siddiqui et al., 2013; Yekezare et al., 2013). 
Perturbations to origin licensing and replication initiation can result in cell death or in genome 
instability leading to oncogenesis (Arentson et al., 2002; Blow and Gillespie, 2008; Yekezare et 
al., 2013). For these reasons, origin licensing control is intimately coordinated with mechanisms 
that govern cell cycle progression. In this work, we focus specifically on current understanding 
of the regulation and function of the Cdt1 protein (Cdc10-dependent transcript 1). Unlike other 
essential licensing proteins, Cdt1 lacks enzymatic activity and shares little resemblance to any 
other protein of known molecular function, yet it is essential for origin licensing in all eukaryotes 
tested. In mammalian cells, small changes in Cdt1 control can lead to catastrophic consequences 
for genome stability, suggesting that Cdt1 regulation is unusually important. Moreover, the 
recent finding that Cdt1 has a second essential role in the cell cycle during mitosis underscores 
the importance of fully understanding its function (Varma et al., 2012). These features make 
Cdt1 unique among the core licensing factors and warrant a thorough up-to-date synthesis of the 
                                                          
1Portions of this chapter previously appeared in Genes (Basel). Modified from: Pozo, P.N. and 
Cook, J.G. Regulation and Function of Cdt1; A Key Factor in Cell Proliferation and Genome 
Stability. Genes. 2017. 8(1):2 
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current knowledge about Cdt1 function, structure, regulation, and how its dysregulation 
contributes to disease. In this work, we focus on understanding mammalian Cdt1, and we are 
informed by key mechanistic insights gleaned from model experimental systems including 
Saccharomyces cerevisiae, Schizosaccharomyces pombe, Xenopus laevis, Drosophila 
melanogaster, and cultured mammalian cells. 
Cdt1 Function 
Mammalian cells replicate billions of DNA base pairs with high fidelity and then 
accurately segregate duplicated genomes to daughter cells each cell cycle. These incredible feats 
are under strict regulation and are tightly linked to cell cycle progression. Cdt1 is required for 
both DNA replication and chromosome segregation, and although these functions are not yet 
fully elucidated, recent advances inspire increasingly detailed models of Cdt1’s role.  
 Origin Licensing 
The first step in eukaryotic DNA replication occurs in G1 and is the sequential loading of 
replication factors at numerous sites in the genome, known as origins of replication. Origins are 
sites where DNA replication initiates during S phase. A typical eukaryotic cell contains between 
400 (yeasts) and as many as >350,000 (human) potential origins (Mechali, 2010; Besnard et al., 
2012; Prioleau and MacAlpine, 2016). Broad distribution of origins on chromosomes ensures 
complete genome duplication within the time allotted for S phase. Replication factor loading at 
origins, known as origin licensing, was first described nearly three decades ago using X. laevis 
egg extracts to determine what factors can induce unscheduled DNA re-replication in vitro 
(Blow and Laskey, 1988). The study concluded that DNA replication requires the recruitment of 
a “Licensing Factor” to DNA during mitosis, thereby setting the stage for DNA synthesis in the 
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subsequent S phase. Furthermore, DNA that was replicated cannot replicate again until the 
following cell cycle because of the inability of the factor(s) to access chromatin. These results 
provided the first model for the control of DNA replication where a Licensing Factor binds 
DNA, is required for the initiation of DNA replication, and becomes deactivated until the 
following mitosis (Blow and Laskey, 1988). Since then, numerous studies have provided 
experimental support for the now-established “replication licensing system” to control precise 
genome duplication once-and-only-once per cell cycle (Siddiqui et al., 2013; Deegan and 
Diffley, 2016). The core licensing factors have since been identified, and they assemble into a 
chromatin-bound macromolecular complex, known as the pre-replication complex (pre-RC). Pre-
RC assembly is a highly cell cycle-regulated process governed in part by the cyclical fluctuation 
of cyclins and the activity of the Cyclin-Dependent Kinases (CDKs) they activate.  
The assembly of pre-RCs occurs during a period of low CDK activity in late mitosis and 
G1 phase. Biochemical and genetic studies in yeast, Xenopus, and mammalian cells identified the 
minimal licensing factors essential for pre-RC assembly (Maine et al., 1984; Cocker et al., 1996; 
Gillespie et al., 2001; Evrin et al., 2009; Remus et al., 2009). These factors are Origin 
Recognition Complex (ORC), Cell Division Cycle 6 (Cdc6), Minichromosome Maintenance 
(MCM), and Cdt1. Eukaryotic ORC is a heterohexamer composed of six distinct subunits, Orc1 
through Orc6. ORC is the only licensing component that directly binds origin DNA, and it is 
required for the nucleation of the pre-RC. Cdc6 is a monomeric protein that is recruited to DNA 
by protein–protein interactions with ORC (Cocker et al., 1996; Coleman et al., 1996; Saha et al., 
1998). Cdc6 and the Orc1–Orc5 subunits are members of the AAA+ family of ATPases which 
are prevalent in many DNA metabolic processes (Neuwald et al., 1999; Borlado and Mendez, 
2008; Li and Stillman, 2012). The MCM complex is the core component of the replicative DNA 
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helicase, and its successful loading onto origin DNA is synonymous with origin licensing. Like 
ORC, MCM is a heterohexamer composed of six distinct subunits, Mcm2 through Mcm7, which 
are also AAA+ proteins. In this review, we will specifically discuss Cdt1 regulation and 
function; for in-depth reviews of ORC, Cdc6, and MCM, the reader is referred to excellent 
contributions by others in the field (Borlado and Mendez, 2008; Li and Stillman, 2012; Bell and 
Botchan, 2013; Deegan and Diffley, 2016). 
Our understanding of the molecular events in origin licensing (illustrated in Figure 1.1) 
comes primarily from pioneering work using both X. laevis egg extracts and purified budding 
yeast licensing proteins (Masai et al., 2010; Siddiqui et al., 2013). Importantly, the strong 
conservation of origin licensing proteins throughout eukaryotic evolution, combined with many 
corroborating studies in mammalian cells, gives confidence that licensing functions elucidated in 
model systems are applicable to human cells; though aspects of their regulation vary by species. 
Pre-RC assembly begins with ORC loading onto presumptive origin DNA. Interestingly, ORC 
DNA binding—particularly in metazoan genomes—is largely independent of DNA sequence, 
but is highly influenced by local chromatin characteristics (Dorn and Cook, 2011; Leonard and 
Mechali, 2013; MacAlpine and Almouzni, 2013). ORC recruits the Cdc6 protein to chromatin to 
await the arrival of Cdt1 bound to the MCM complex to form a pre-RC (Masai et al., 2010; 
Siddiqui et al., 2013). In a process not yet fully understood (Riera et al., 2013; Yardimci and 
Walter, 2014), the concerted action of ORC, Cdc6 and Cdt1 results in topological loading of an 
MCM heterohexamer onto DNA with double-stranded DNA passing through the MCM central 
channel (Evrin et al., 2009; Remus et al., 2009). Cdc6 and then Cdt1 are released, followed by a 
second round of Cdc6 and Cdt1-MCM recruitment (Ticau et al., 2015). The second MCM 
complex is loaded such that the MCM N-termini face one another to create double hexameric  
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Figure 1.1. 
 
Figure 1.1. Origin Licensing. MCM hexamers are loaded by Cdt1, Cdc6, and ORC at 
presumptive chromosomal origins during phase. 
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rings. This arrangement sets each MCM complex in the correct orientation to establish 
bidirectional forks upon origin firing (Sun et al., 2013; Li et al., 2015). Only the correct loading 
of MCM double hexamers renders a locus competent for subsequent replication initiation, or 
“firing”, during S phase. MCM loaded in G1 is not active as a helicase, and origin DNA is 
thought to remain double-stranded until origin firing. Origin firing requires phosphorylation 
events from CDKs and a replication-specific kinase, Dbf4-dependent kinase (DDK). These 
kinases promote the recruitment of additional essential helicase components, Cdc45 and GINS, 
to activate DNA unwinding (Ilves et al., 2010; Labib, 2010; Tanaka and Araki, 2013). 
Origin licensing can begin as early as telophase, as soon as nuclear envelopes have 
formed around the segregated mitotic chromosomes, though it is not clear if licensing begins this 
early in all species or cell types (Dimitrova et al., 2002; Xouri et al., 2007; Symeonidou et al., 
2013). Licensing continues throughout G1 and ceases at the G1/S phase transition. Somewhat 
surprisingly, eukaryotic cells load many more MCM double hexamers than the number of DNA-
bound ORCs (Edwards et al., 2002). At least 10-fold more origins can be licensed than are 
strictly required for complete replication under normal circumstances, though the degree of 
origin licensing likely varies among cells, tissues, and species (Woodward et al., 2006; Powell et 
al., 2015; Hyrien, 2016). In vitro, loaded MCM double hexamers can slide along DNA away 
from ORC, leaving space near ORC for another round of MCM loading (Evrin et al., 2009; 
Remus et al., 2009), and recent results suggest that MCMs may also slide in vivo (Gros et al., 
2015; Powell et al., 2015). In a typical S phase, some MCM complexes that had been loaded in 
G1 are activated as part of the regular replication program, whereas others initiate replication in 
response to nearby stalled or damaged replication forks to ensure replication completion. Origins 
that are only utilized under the latter conditions of replication stress are termed “dormant” 
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origins, and they safeguard the genome against under-replication (Ge et al., 2007; Ibarra et al., 
2008; McIntosh and Blow, 2012).  
Notably, Cdt1 is essential for MCM loading in all eukaryotes in which it has been tested, 
but its precise molecular function in origin licensing is not fully clear (Maiorano et al., 2000; 
Nishitani et al., 2000; Rialland et al., 2002). Cdt1 interacts directly with the MCM complex in 
solution and with both ORC and Cdc6 (Cook et al., 2004; Ferenbach et al., 2005; Chen et al., 
2007; Zhang et al., 2010; Fernandez-Cid et al., 2013). In the absence of Cdt1, MCM complexes 
are never recruited to DNA (Maiorano et al., 2000; Devault et al., 2002; Tanaka and Diffley, 
2002). In that regard, one likely role for Cdt1 in licensing is as a molecular bridge or “courier” to 
deliver soluble MCM complexes to DNA-bound ORC/Cdc6. In support of that model, recent 
single molecule studies using purified yeast licensing proteins discovered that Cdt1 is rapidly 
released upon successful loading of each MCM complex (Ticau et al., 2015). By following 
individual labeled proteins, Ticau et al. showed Cdt1 and Cdc6 release between the two rounds 
of MCM loading. This rapid shuttling between the bound and soluble states for both Cdt1 and 
Cdc6 suggests that each molecule could participate in many origin licensing events. Perhaps for 
this reason, the levels of both Cdc6 and Cdt1 are highly regulated during the cell cycle to prevent 
inappropriate origin licensing.  
The MCM complex is a hexameric ring even in solution before it is loaded (Evrin et al., 
2009; Ilves et al., 2010; Boskovic et al., 2016). MCM loading is therefore not a process of 
assembling the heterohexamers on DNA from their component subunits, but rather, loading pre-
assembled hexamers onto DNA. DNA passes through a side “gate” between the Mcm2 and 
Mcm5 subunits, and much speculation currently swirls around the mechanism and dynamics of 
MCM gate opening and closing (Bochman and Schwacha, 2010; Samel et al., 2014). Moreover, 
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the MCM double hexamer central channels contain double-stranded DNA in G1 but the active 
MCM helicase at replication forks encircles single-stranded DNA and displaces the second 
strand (Boos et al., 2012; Tanaka and Araki, 2013; Trakselis, 2016). At least in vitro, yeast Cdt1 
is not released from the complex until MCM is successfully loaded (Ticau et al., 2015). Its 
persistence during the actual loading reaction suggests that Cdt1 does more than simply hand 
MCM off to ORC and Cdc6. Cdt1 may be required to maintain MCM in the proper orientation or 
conformation for successful DNA loading. If so, then how Cdt1—or ORC and Cdc6 for that 
matter—load the two MCM complexes in opposite orientations remains to be discovered 
(Yardimci and Walter, 2014; Deegan and Diffley, 2016). 
De-Regulated Origin Licensing 
The requirement that normal DNA replication produce exactly one copy of each 
chromosome puts important constraints on origin utilization. Specifically, each origin that fires, 
must fire no more than once per cell cycle. Origin re-firing results from re-licensing DNA that 
has already been duplicated. A second round of initiation from the re-licensed origins leads to 
duplicating sequences more than once, a phenomenon known as re-replication. Interestingly, re-
replication is induced in the final cell cycles of some tissues to increase DNA copy number, most 
notably in D. melanogaster, but such cells are not normally destined to divide again. Re-
replication is distinct from scheduled genome re-duplication which results from skipping 
cytokinesis; re-duplication typically produces quantile increases in ploidy whereas 
developmentally programmed re-replication targets only some loci (Lee et al., 2009; Nordman 
and Orr-Weaver, 2012; Fox and Duronio, 2013). In contrast to developmentally programmed re-
replication, unscheduled re-replication is an aberrant phenomenon associated with genome 
instability (Li and Jin, 2010; Truong and Wu, 2011). Indeed, re-replication can be the initiating 
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event for gene amplification (Green et al., 2010), a frequent observation in cancer cells. Partial 
re-replication can be experimentally induced by deregulating MCM loading factors, and in 
human cells, re-replicated sequences are detectable essentially randomly throughout the genome 
(Klotz-Noack et al., 2012). Re-replication is typically associated with markers of replication 
stress and evidence of DNA damage response pathway activation (Vaziri et al., 2003; Melixetian 
et al., 2004; Green and Li, 2005; Davidson et al., 2006).  
To avoid re-replication, all origin licensing activity ends once S phase begins. There is no 
known means to directly reverse inappropriate origin licensing, so a network of overlapping 
inhibitory mechanisms is needed to prevent all origin licensing outside of G1 phase. These 
licensing controls target each member of the pre-RC from the onset of S phase through mitosis. 
Mammalian Cdt1 is inhibited by at least four distinct pathways, suggesting that it is among the 
most important to inhibit; we discuss each of these mechanisms in more detail in Section 4. 
Many licensing factors are inactivated by phosphorylation via the same CDK activity that 
triggers origin firing (in human cells primarily cyclin A/Cdk2). Interestingly, the outcomes of 
these phosphorylations may vary depending on the licensing factor being targeted and in which 
organism, though the end result is always to inhibit origin relicensing. For example, in S. 
cerevisiae, Cdc6 phosphorylation by CDK targets it for ubiquitin-mediated proteolysis, whereas 
phosphorylation of human and Xenopus Cdc6 induces nuclear export (Saha et al., 1998; Elsasser 
et al., 1999; Petersen et al., 1999; Drury et al., 2000). On the other hand, in S. cerevisiae, MCM 
and Cdt1 are subjected to CDK-mediated nuclear export (Nguyen et al., 2000; Tanaka and 
Diffley, 2002). In S. cerevisiae, ORC subunits are inhibited by CDK-dependent phosphorylation 
by disrupting their ATPase activity (Makise et al., 2009) and blocking interaction with Cdt1 
(Chen and Bell, 2011), whereas in human and Xenopus, CDK-dependent ORC phosphorylation 
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induces release from origins and/or degradation of the Orc1 subunit (Rowles et al., 1999; 
Mendez et al., 2002; Li et al., 2004). Regardless of the species-specific details, the aggregate 
result is inhibiting pre-RC assembly by neutralizing interactions or triggering licensing factor 
degradation.  
Incomplete origin licensing in G1 can also be a source of genome instability. In 
untransformed human cells, significantly slowing origin licensing induces a delay in S phase 
onset by delaying the activation of Cdk2 (Shreeram et al., 2002; Machida et al., 2005; Nevis et 
al., 2009). This “origin licensing checkpoint” requires p53, meaning that p53-deficient cells can 
enter S phase with severely underlicensed chromosomes which renders them susceptible to S 
phase failure (Shreeram et al., 2002; Machida et al., 2005; Nevis et al., 2009). Despite extensive 
documentation of the licensing checkpoint phenomenon in several labs and in multiple cell lines, 
precisely how licensed or unlicensed DNA is detected to affect Cdk2 activity is still unclear. 
Moreover, “sufficient” origin licensing is not simply a matter of the total number of loaded 
MCM hexamers per genome since their distribution is also critical. A recent study by Moreno et 
al. found that moderate licensing inhibition that does not cause a cell cycle delay, nonetheless 
increases the likelihood that regions of unreplicated DNA persist through mitosis (Moreno et al., 
2016). Thus, Cdt1 activity and origin licensing must be efficiently blocked in S phase and G2 to 
prevent re-replication but must be fully induced in G1 to ensure sufficient origin licensing and 
complete genome duplication. 
Cdt1-Associated Chromatin Modifiers 
Licensing factors must have local access to origin DNA to assemble and load MCM 
helicases. The chromatin environment at origins thus has a large impact on origin licensing. Post-
translational histone modifications, such as methylation and acetylation, can greatly affect DNA 
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accessibility which may facilitate ORC binding, MCM loading, and/or origin firing. In addition, 
at S. cerevisiae origins which have been mapped with high resolution, nucleosome positioning 
also plays a role in determining ORC localization and activity (reviewed in (Berbenetz et al., 
2010; Dorn and Cook, 2011; Prioleau and MacAlpine, 2016)). In the majority of eukaryotic 
genomes, DNA sequence is a minor determinant of origin location. The model that has emerged 
is that ORC is recruited to DNA not by a specific nucleotide sequence, but rather by aspects of 
local chromatin structure and DNA accessibility. Some evidence supporting this model is the 
presence of a BAH (Bromo Adjacent Homology) domain in Orc1, the largest subunit of ORC. 
The BAH domain specifically recognizes histone post-translational modifications (PTMs) 
enriched at replication origins, and is required for proper ORC DNA loading (Muller et al., 2010; 
Kuo et al., 2012).  
Once ORC has bound, the local chromatin environment may require additional 
modifications to permit efficient origin licensing. Several histone-modifying enzymes associate 
with licensing components and are predicted to modify nucleosomes to promote DNA 
accessibility; some of these enzymes have been identified as Cdt1 partners. One such chromatin 
modifier is histone acetyltransferase bound to Orc1 (Hbo1), which as its name implies, was first 
discovered as an Orc1-binding protein and later shown to bind the Mcm2 subunit of MCM, and 
Cdt1 (Iizuka and Stillman, 1999; Burke et al., 2001; Miotto and Struhl, 2008). Hbo1 is highly 
conserved, and orthologs in D. melanogaster and S. cerevisiae have also been linked to DNA 
replication (Aggarwal and Calvi, 2004; Zou and Bi, 2008). In human cells, Hbo1 is responsible 
for the bulk of histone H4 acetylation genome-wide (Saksouk et al., 2009). Since histone H4 
acetylation generally correlates with active chromatin and accessible DNA, increased local 
histone acetylation could promote origin licensing. In addition, Hbo1 was specifically detected at 
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several known human replication origins during G1 coincident with Cdt1 origin association 
(Miotto and Struhl, 2008). Further studies found that Cdt1 promoted chromatin openness in 
association with Hbo1 during G1, likely increasing local chromatin accessibility and facilitating 
MCM loading (Wong et al., 2010). In addition to Hbo1, early proteomic screens for Cdt1-
interacting proteins discovered the GRWD1 protein (glutamate-rich WD40 repeat containing 1), 
a histone binding protein (Sugimoto et al., 2015). Follow up studies suggested that GRWD1 
regulates chromatin openness during MCM loading at replication origins (Sugimoto et al., 2015) 
and may cooperate with a chromatin remodeler, SNF2H (Sugimoto et al., 2011). On the other 
hand, during S phase and G2 Cdt1 may contribute to inhibiting origin licensing by recruiting the 
HDAC11 histone deacetylase. Local histone deacetylation would presumably reduce chromatin 
accessibility and inhibit origin relicensing (Glozak and Seto, 2009; Wong et al., 2010). 
Interestingly, association of the inhibitor protein geminin with Cdt1 during S phase enhanced the 
recruitment of HDAC11 to origins to further inhibit origin licensing (Wong et al., 2010).  
Cdt1 in Chromosome Segregation 
Surprisingly, human Cdt1 is required not only for origin licensing but also for mitosis. As 
a consequence, asynchronously-growing cells, depleted of Cdt1, accumulate in both G1 phase 
and G2 phase because they can neither license origins, nor progress through the metaphase-to-
anaphase transition. This essential mitotic function was first discovered in a screen for Cdt1-
interacting proteins that identified human Hec1 (Highly Expressed in Cancer 1), a component of 
the NDC80 kinetochore–microtubule attachment complex (Varma et al., 2012). Hec1 is 
conserved from yeast to mammals, but the mitotic Cdt1 function is not evident in either budding 
or fission yeast (Hofmann and Beach, 1994; Devault et al., 2002); more work is required to 
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determine if Cdt1 has mitotic functions in invertebrates such as D. melanogaster or 
Caenorhabditis. elegans or in non-mammalian vertebrates such as X. laevis. 
A fraction of human Cdt1 molecules localize to kinetochores in mitosis, and this 
localization requires Hec1; Hec1 localization is unaffected by Cdt1 depletion. Cdt1 interacts with 
and is recruited to kinetochores via a unique “loop” domain in Hec1 that interrupts an otherwise 
long coiled-coil central span. Both depletion of Cdt1 prior to mitosis or mutationally altering the 
Hec1 loop domain to block Cdt1 binding and recruitment resulted in prometaphase arrest with an 
unsatisfied spindle assembly checkpoint (Varma et al., 2012). Importantly, the mitotic defect in 
Cdt1-depleted cells can be separated from potential indirect effects of incomplete DNA 
replication by depleting Cdt1 after origin licensing is complete and S phase has already begun 
(Varma et al., 2012).  
It is not yet clear precisely how Cdt1 promotes stable kinetochore–microtubule 
attachments since it is not required for the localization of any other kinetochore proteins tested 
thus far. One clue to its function came from analysis of the conformation of the NDC80 complex 
in vivo using super-resolution microscopy. The structure of the NDC80 complex 
(Hec1/Nuf2/Spc24/Spc25) indicates that the loop region of Hec1 where Cdt1 binds is a point of 
flexibility in an otherwise long and rigid coiled-coil domain. Prior work by Wang et al. 
supported the notion that the loop region corresponds to a hinge or joint in the complex (Wang et 
al., 2008). The N-terminal domains of Hec1 and Nuf2 directly contact kinetochore microtubules, 
whereas the Spc24 and Spc25 subunits connect the complex to other kinetochore proteins (Wan 
et al., 2009; Alushin et al., 2010). In prometaphase, prior to attachment, the two ends of the 
NDC80 complex are relatively close together, whereas at stably-attached kinetochores in 
metaphase, the two ends of the complex are considerably further apart (Wan et al., 2009). 
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Mutation of the loop domain or depletion of Cdt1 prevented this extended NDC80 conformation 
(Varma et al., 2012). Thus, Cdt1 supports a microtubule-dependent conformational extension in 
its partner, the NDC80 complex, by interaction with the major point of flexibility conferred by 
the loop region of Hec1.  
Many important questions about Cdt1 mitotic function remain: what other (if any) 
microtubule-associated or kinetochore partners bind Cdt1? The Hec1-interacting domain on Cdt1 
is not yet known, but identifying this region is a first step towards generating separation-of-
function alleles that are impaired for only origin licensing or only kinetochore–microtubule 
attachment. How, precisely, does Cdt1 affect the conformation of NDC80? Moreover, as 
described below (see Section 4.4), Cdt1 is heavily phosphorylated during G2 phase and mitosis. 
What role does Cdt1 phosphorylation play in its intermolecular interactions and function at 
kinetochores? Clearly, much remains to be learned about this novel role for Cdt1 and how it 
relates to the more famous origin licensing function. 
Cdt1 Structure 
In most species, Cdt1 is a ~60–70 kDa protein; S. pombe Cdt1 is somewhat smaller at 
~50 kDa whereas the D. melanogaster Cdt1 is ~82 kDa. (D. melanogaster Cdt1 is named 
“double-parked”, abbreviated Dup, but nearly all other species use “Cdt1” as the protein and 
gene name). Although each subunit of ORC and MCM, Cdc6 and Cdt1 are conserved in all 
eukaryotic genomes examined, the degree of sequence conservation is lowest for Cdt1 compared 
to the other licensing proteins. Indeed, the low sequence similarity between human and S. 
cerevisiae Cdt1 coupled with the unusual history of metazoan Cdt1 being identified first, led to a 
brief period in the field when it was not clear if budding yeast had a Cdt1 ortholog. Focused 
sequence searches coupled with functional tests ultimately identified the yeast Cdt1 ortholog 
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(Devault et al., 2002). Unlike nearly all other licensing components which are homologous to 
AAA+ ATPases, Cdt1 is not an enzyme, and the Cdt1 protein sequence bears little similarity to 
other proteins of known molecular activity. Although the Cdt1 sequence gives little insight into 
its function, some information about interacting regions, post-translational modifications, and 
domain structures is available which we describe here. 
Functional Domains 
Multispecies Cdt1 protein sequence alignments reveal regions that are relatively well-
conserved and regions which share considerably less conservation. Not surprisingly, the regions 
of low conservation are particularly prominent in comparisons of mammalian and fungal Cdt1 
species. Using human Cdt1 as a reference, Figure 1.2 includes pairwise sequence comparisons 
between human Cdt1 and Cdt1 sequences from several model organisms in four Cdt1 domains, 
the N-terminus (amino acids [aa] 1–166), the central domain (aa 167–374), a short “linker” 
region (aa 375–406), and the MCM binding domain (aa 407–546). Sites of protein–protein 
interactions and phosphorylations are also marked. The N-terminal sequences of both model 
yeast Cdt1 sequences are generally quite short and they bear little resemblance relative to their 
metazoan counterparts. On the other hand, sections of higher relative homology suggest regions 
important for functions that are conserved in all species, such as interaction with other origin 
licensing components.  
Traditional truncation and mutagenesis approaches identified Cdt1 domains required for 
protein interactions and for specific aspects of origin licensing function (Ferenbach et al., 2005; 
Khayrutdinov et al., 2009; Jee et al., 2010). The most comprehensive of these studies by 
Ferenbach et al. validated and/or delineated the MCM binding domain, geminin binding domain, 
and minimal licensing activity domain using recombinant fragments of X. laevis Cdt1 added to  
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Figure 1.2. 
 
 
Figure 1.2. Human Cdt1 structure. Diagram of Cdt1 divided into four segments based on 
alignments and structural studies. Pairwise comparisons to the human sequence for 
representative eukaryotic Cdt1 orthologs within each segment are reported as % identity/% 
similarity; NR indicates regions in fungal sequences too short or dissimilar for comparison. 
Regions responsible for recognition by E3 ubiquitin ligases (degrons), a region enriched in 
proline, glutamic acid, serine, and threonines (PEST domain), geminin binding, MCM) binding, 
and a putative linker domain (enriched in phosphorylation sites) are marked. Phosphorylation 
sites in human Cdt1 that are conserved in at least one other vertebrate sequence are marked as 
ball-and-stick icons: green = Cyclin-Dependent Kinases (CDK)/Mitogen-Activated Protein 
Kinases (MAPK) sites validated by mutagenesis and functional studies, dark gray = putative 
CDK/MAPK sites (serine-proline or threonine-proline) identified by mass spectrometry 
(Hornbeck et al., 2015), light gray = conserved sites detected by mass spectrometry distinct from 
the CDK/MAPK substrate consensus. Ribbon diagrams of the two segments for which structures 
have been determined are shown; central domain PDB 2WVR (human) and C-terminal domain 
PDB 3A4C (mouse) (Lee et al., 2004; De Marco et al., 2009). A diagram of the yeast MCM2-7 
complex bound to full-length Cdt1 derived from tracing the single-particle analysis results from 
Sun et al. 2013 is also shown. 
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oocyte lysates (Ferenbach et al., 2005). The shortest fragment that complemented Cdt1-depleted 
lysates for licensing corresponds to human Cdt1 aa 243–546 (Ferenbach et al., 2005). The 
finding that the N-terminal 242 amino acids (corresponding to human aa 1–170) are dispensable 
for licensing activity, plus the fact that this region is the least-well-conserved is consistent with 
the notion that the N-terminal region is the target of species-specific regulation rather than 
essential for Cdt1 function.  
Crystal Structures/Cryo-EM Structures 
Currently, no atomic structure for full-length Cdt1 from any species is available. One 
challenge for structure studies of Cdt1 is that both the N-terminal domain and part of the linker 
domain are predicted to be intrinsically disordered. Using two different prediction tools, the N-
terminal 166 amino acids of human Cdt1 has a probability of disorder at each position greater 
than 65% (Peng and Kurgan, 2015; Zhang et al., 2017). The linker is relatively short, but it also 
contains a region of high predicted disorder. Trimming these regions to isolate the central 
domain or the C-terminal domain yielded fragments that were compatible with crystallography, 
and their exclusion from the structural studies is consistent with the notion that they are flexible. 
The atomic structure of the central domain was first solved for mouse Cdt1 (aa 172–368) in 
complex with the geminin inhibitor protein (Lee et al., 2004), and the corresponding human Cdt1 
protein fragment (aa 166–353) was later crystallized (De Marco et al., 2009). A recent search of 
a database of protein structures for nearest neighbors to this central domain identified some 
similarity to winged-helix domains (Holm and Rosenstrom, 2010). Otherwise, the central domain 
structure is relatively unique. 
The C-terminal domain (human 408–546) interacts with the MCM complex. This isolated 
fragment can directly bind a C-terminal fragment from the Mcm6 subunit suggesting that this 
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interaction is one of the direct contacts between Cdt1 and the MCM complex in vivo (Wei et al., 
2010). This protein fragment was characterized by both X-ray crystallography and Nuclear 
Magnetic Resonance as a winged helix domain (Khayrutdinov et al., 2009; Jee et al., 2010; Liu 
et al., 2012). Interestingly, this winged-helix shows some structural similarity to the central 
domain of Cdt1 itself (Jee et al., 2010). Although winged helices are most well-known for roles 
in nucleic acid binding, the C-terminal Cdt1 winged-helix is unlikely to form stable interactions 
with DNA. Positions of key alpha helices are incompatible with DNA binding compared to 
winged-helix domains in canonical DNA binding proteins, and Cdt1 lacks charged patches that 
would stabilize DNA binding (Jee et al., 2010). Moreover, Cdt1 chromatin association in cells 
requires ORC (Maiorano et al., 2000; Chen and Bell, 2011), and purified yeast Cdt1 does not 
bind origin DNA in the absence of ORC (Remus et al., 2009). It is most likely therefore that the 
C-terminal Cdt1 winged-helix is of the type that mediates protein–protein rather than protein-
nucleic acid interactions. In support of that model, mutational alteration of a subset of charged 
surface residues of the C-terminal domain impaired MCM binding in vitro (Jee et al., 2010; Liu 
et al., 2012), and several of the corresponding mutations to budding yeast Cdt1 impaired cell 
growth (Jee et al., 2010). These biochemical data corroborated findings from a separate co-
crystallographic study which demonstrated a direct Cdt1–Mcm6 interaction conferred by the 
Cdt1 C-terminal domain (Khayrutdinov et al., 2009).  
Although these studies provide important structural information, key aspects of Cdt1 
structure are still not known. Yeast Cdt1 can directly bind the Orc6 subunit of ORC (Chen et al., 
2007), but the Cdt1 domain responsible is not known nor are potential Cdt1 regions that bind 
other subunits of MCM. As-yet uncharacterized Cdt1 interactions with ORC and MCM are likely 
required for origin licensing and/or regulating Cdt1 function. In that regard, a recent paper 
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described a novel and still uncharacterized “PEST” (rich in proline [P], glutamic acid [E], serine 
[S], and threonine [T]) domain in mouse Cdt1 (Figure 1.2) (Coulombe et al., 2013). Cdt1 is 
abundant during G2 phase but is poorly associated with chromatin (Ballabeni et al., 2004; Xouri 
et al., 2007; Coulombe et al., 2013). Truncating the PEST domain caused premature re-
association of Cdt1 with chromatin during G2 and increased the likelihood of re-replication 
(Coulombe et al., 2013). Given that Cdt1 chromatin binding requires ORC interaction (Maiorano 
et al., 2000), this PEST domain may indicate a region required for ORC binding. 
Several studies using single particle electron microscopy coupled with labeling strategies 
have suggested how full-length budding yeast Cdt1 interacts with the MCM complex and in a 
licensing intermediate containing ORC, Cdc6, Cdt1 and MCM (Riera et al., 2013; Sun et al., 
2013). These models are consistent with the biochemical studies detecting Cdt1 in direct contact 
with Mcm6 (Chen and Bell, 2011). In addition to this contact with Mcm6, Cdt1 appears to 
contact additional MCM subunits, especially extensive interaction with Mcm2 (Figure 1.2). This 
location is relatively close to the interface of Mcm2 with Mcm5 through which DNA passes 
during the loading reaction (Bochman and Schwacha, 2010; Samel et al., 2014). In this position, 
Cdt1 is well-placed to affect the conformation of the MCM complex during loading in ways that 
may stabilize either the open or closed MCM conformation. 
Cdt1 Regulation 
To properly license origins for DNA replication in G1 and block origin licensing from the 
onset of S phase through mitosis, multiple independent mechanisms control human Cdt1 
abundance and function (illustrated in Figure 1.3). Although other licensing proteins are also 
under cell cycle control, Cdt1 is subject to the most extensive regulation in human cells, 
suggesting that it is perhaps the most important licensing factor to regulate in mammalian cells.  
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Figure 1.3. 
 
 
Figure 1.3. Human Cdt1 regulation during a single cell cycle. The blue line indicates relative 
Cdt1 protein abundance. (A). Cdt1 is dephosphorylated in early G1 by an unknown phosphatase; 
(B) Cdt1 participates with ORC and Cdc6 to load MCM hexamers onto DNA; (C) Proliferating 
Cell Nuclear Antigen (PCNA) loaded at DNA replication forks is bound by the Cdt1 PCNA-
Interacting Protein (PIP) degron, and the complex is recognized for ubiquitylation and 
subsequent proteasome-mediated destruction by CRL4Cdt2; (D) Cdt1 is phosphorylated at Thr29 
by cyclin A/Cdk2 to create a phosphodegron recognized for ubiquitylation by CRL1Skp2. The 
combined action of two E3 ubiquitin ligases drives Cdt1 degradation in S phase; (E) The 
geminin protein begins to accumulate in early S phase, and peaks in late S phase and G2. 
Geminin binding blocks Cdt1 origin licensing function; (F) During late S phase and G2, mitotic 
kinases—especially cyclin A/Cdk1 and the stress-activated MAP kinases p38 and c-Jun N-
terminal Kinase (JNK)—phosphorylate Cdt1; Cdk1 also inactivates CRL4Cdt2; (G) A subset of 
Cdt1 molecules is recruited to kinetochores in mitosis through interaction with the loop domain 
of Hec1. Cdt1 is required for stable kinetochore–microtubule attachment. 
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The ultimate outcome is a collection of cell cycle-dependent regulatory mechanisms that allow 
Cdt1 to function efficiently in its origin licensing role during G1, prevent origin relicensing in S 
and G2 phase, and permit Cdt1 participation in kinetochore microtubule attachment during 
mitosis.  
Transcriptional Control 
The first Cdt1 ortholog was cloned 20 years ago in a screen for fission yeast transcripts 
that are upregulated at the G1 to S transition (Hofmann and Beach, 1994). In fission yeast, the 
transcription factor driving Cdt1 expression is Cell Division Cycle 10 (Cdc10), which is 
responsible for transcriptional induction of many genes important for the G1 to S phase transition 
(Whitehall et al., 1999). The analogous function in metazoans is the responsibility of the E2F 
family of transcription factors, though the protein sequences of Cdc10 and E2F themselves are 
unrelated (Cross et al., 2011; Duronio and Xiong, 2013). The human CDT1 gene has three 
putative E2F responsive elements in its promoter region, is activated by E2F with peak 
expression in late G1, and is inhibited by the Rb tumor suppressor (Yoshida and Inoue, 2004). 
Other studies have suggested that Cdt1 is also under the transcriptional control of the c-Myc 
proto-oncoprotein and the Gli1 component of the hedgehog signaling pathway (Valovka et al., 
2013; Zhang et al., 2016). Of note, Cdt1 protein abundance in proliferating cells peaks in G1 and 
G2 rather than S phase (Figure 1.3), but the transcriptional upregulation generally supports Cdt1 
expression during proliferation. Aside from the documented regulation by E2F and possibly c-
myc and Gli1, little else is known about how the production of Cdt1 is regulated. For instance, 
no evidence for alternative splicing, regulation by microRNAs or translational control has yet 
emerged, though such possibilities should be explored.  
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 Ubiquitin Mediated Proteolysis in S Phase 
A key aspect of re-replication control in metazoans is ubiquitin-mediated Cdt1 
degradation during S phase. This regulation occurs in all eukaryotes except for budding yeast in 
which a Cdt1-MCM complex is exported from the nucleus to the cytoplasm during S phase 
(Nguyen et al., 2000; Tanaka and Diffley, 2002). In mammalian cells, Cdt1 degradation in S 
phase is mediated by two independent E3 ubiquitin ligase complexes, CRL1Skp2 (also known as 
SCF; reviewed in (Petroski and Deshaies, 2005)) and CRL4Cdt2 (Abbas and Dutta, 2011; Havens 
and Walter, 2011). Like many substrates of CRL1Skp2, Cdt1 is only bound for productive 
ubiquitylation once it is phosphorylated by CDK. In human Cdt1, this “phosphodegron” is 
created by Cdk2-mediated phosphorylation at threonine 29. Thr29 phosphorylation is then 
recognized by Skp2, a substrate adaptor, to trigger ubiquitylation (Li et al., 2003; Liu et al., 
2004; Sugimoto et al., 2004). A nearby serine at position 31 that matches the minimal CDK 
substrate consensus is also phosphorylated in cells, but it plays a minor role in recruiting Cdt1 to 
CRL1Skp2.  
Although manipulations that block Cdt1 Thr29 phosphorylation prevent ubiquitylation by 
CRL1Skp2, such manipulations do not substantially stabilize Cdt1 during S phase. Even in the 
absence of CRL1Skp2 targeting, Cdt1 is ubiquitylated and degraded by a second E3 ubiquitin 
ligase, CRL4Cdt2 (Nishitani et al., 2006) (Cdt2 was identified in the same screen that discovered 
Cdt1, but the Cdt1 and Cdt2 sequences are unrelated (Hofmann and Beach, 1994)). Unlike 
targeting by CRL1Skp2, Cdt1 ubiquitylation by CRL4Cdt2 is not stimulated by Cdt1 
phosphorylation, but instead requires a ternary interaction among Cdt1, the substrate adapter 
Cdt2, and DNA-loaded Proliferating Cell Nuclear Antigen (PCNA). PCNA is a homotrimer that 
is loaded by Replication Factor C at replication forks and serves as the processivity factor for 
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DNA polymerase during DNA replication. DNA-bound PCNA is also a platform for a host of 
proteins that bind PCNA through short linear motifs known as PCNA-Interacting Protein (PIP) 
boxes (Havens and Walter, 2009). The Cdt1 PIP box is special in that it not only binds PCNA 
but also triggers degradation and is thus termed a “PIP degron.” PCNA is only loaded during 
DNA synthesis, and this loading event is required for Cdt1 recognition by CRL4Cdt2; thus this 
mode of Cdt1 degradation has been termed “replication-coupled destruction” (Havens and 
Walter, 2009). Since the trigger for CRL4Cdt2-mediated degradation is PCNA DNA loading, PIP 
degron-containing Cdt1 proteins are also degraded after DNA damage because PCNA is loaded 
during DNA repair (Higa et al., 2003). 
Mutations to the human Cdt1 PIP degron alone have only modest effects on S phase 
degradation in otherwise unperturbed cells. On the other hand, a combination of PIP degron 
mutations with mutations that block Cdt1 phosphorylation at Thr29 stabilizes Cdt1 during S 
phase and induces substantial re-replication (Nishitani et al., 2004). Near the end of S phase, 
human Cdt1 re-accumulates, but this re-accumulation is not strictly because PCNA is no longer 
DNA loaded. CRL4Cdt2 is globally inhibited as cells approach G2, leading to re-accumulation of 
all of its substrates (Rizzardi et al., 2015). Cdt1 is clearly not targeted by CRL1Skp2 in G2 phase 
either, although cyclin A-dependent activity is still high. The mechanism preventing CRL1Skp2-
mediated Cdt1 degradation in G2 is still unknown. One potential addition to Cdt1 stability 
control is the recent report that Cdt1 abundance is sensitive to the deubiquitylating enzyme, 
Usp37 (Hernandez-Perez et al., 2016). Thus, Cdt1 re-accumulation could be as much a 
consequence of increased deubiquitylation as it is a result of decreased ubiquitylation. 
Somewhat surprisingly and despite being a particularly potent inducer of S phase 
destruction (Coleman et al., 2015), the PIP degron is not conserved in all Cdt1 proteins—not 
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even among all mammalian Cdt1 sequences. PIP degron sequences are not evident in the cow, 
pig, sheep, or rabbit Cdt1 sequences, though Cdt1 PIP degrons are found in nematode, fruit fly, 
zebrafish, chicken, rat, mouse, baboon and many other species (J.G.C. unpublished observation 
and (Havens and Walter, 2011)). Moreover, CRL1Skp2-mediated degradation to reinforce 
CRL4Cdt2-mediated degradation may not be universal among metazoans (e.g., X. laevis Cdt1). In 
species where it appears that only one E3 ligase targets Cdt1 during S phase, the presence of 
stronger licensing inhibitory mechanisms that target other pre-RC components may have allowed 
the second E3 pathway to be lost.  
Inhibition by Geminin 
Unlike nearly all components of the replication licensing system, human Cdt1 was not 
cloned strictly on the basis of sequence homology to a yeast ortholog. In fact, the fission yeast 
Cdt1 was not directly investigated as a licensing protein until after the metazoan Cdt1 proteins 
were functionally characterized. Human Cdt1 was isolated both by sequence similarity to D. 
melanogaster and X. laevis orthologs and as the target of a re-replication inhibitor protein, 
geminin (Maiorano et al., 2000; Whittaker et al., 2000; Wohlschlegel et al., 2000). Geminin 
itself was cloned from biochemical screens for X. laevis proteins that are degraded in mitosis 
(McGarry and Kirschner, 1998). Of note, neither budding nor fission yeast harbor a geminin 
ortholog. Human geminin is abundant during S phase and G2, is degraded at anaphase, and is 
least abundant during G1 phase. Geminin is a substrate of the APC/C (Anaphase-Promoting 
Complex/Cyclosome) (McGarry and Kirschner, 1998), an E3 ubiquitin ligase which promotes 
geminin degradation from late mitosis and throughout G1 phase (McLean et al., 2011; Min and 
Lindon, 2012).  
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Artificially elevating geminin concentration in G1 blocks MCM loading, but the 
mechanism of that inhibition was not known at the time geminin was first characterized 
(McGarry and Kirschner, 1998). An effort to gain insight into how geminin inhibits licensing by 
identifying partners yielded a tight-binding partner in human lysates, human Cdt1. Moreover, 
supplementing geminin-inhibited X. laevis lysates with additional human Cdt1 reversed the 
inhibitory effects of geminin on origin licensing and DNA replication (Wohlschlegel et al., 
2000). Mutations in Cdt1 that alter geminin binding also have higher licensing activity in vitro 
compared to wild-type Cdt1 (You et al., 2016). Like Cdt1, geminin has at least one alternative 
function outside the licensing system; geminin regulates gene expression during development 
(Del Bene et al., 2004; Luo et al., 2004; Yang et al., 2011). 
Geminin is a dimer that forms a stable 2:1 complex with monomeric Cdt1 both on 
chromatin and in the nucleoplasm. Geminin binds the central region of Cdt1 (Figure 1.2), and 
indeed both high-resolution structures of this Cdt1 domain are in complex with geminin; 
possibly because the tight binding facilitated crystallization (Lee et al., 2004; De Marco et al., 
2009). Interestingly, the human crystal structure consists of a Cdt1 and geminin heterohexamer 
composed of two Cdt1 and four geminin polypeptides; this structure is essentially a dimer of the 
trimer observed in the mouse structure. Based on this and other observations, De Marco et al. 
suggested that the trimer is permissive for licensing, whereas the hexamer corresponds to the 
inhibited form (De Marco et al., 2009). If true, then only high concentrations of geminin, such as 
those found in mid-to-late S phase and G2, would be effective for forming hexamers and 
preventing re-replication. In this scenario, re-replication control in early S phase should rely 
more heavily on Cdt1 degradation and mechanisms that target ORC, Cdc6, and MCM than on 
geminin because geminin is less abundant in early S phase. 
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How does geminin inhibit Cdt1 activity? In vitro, geminin prevents the association of 
Cdt1 with MCM complexes (Yanagi et al., 2002; Cook et al., 2004) and also blocks Cdt1 
binding to Cdc6 (Cook et al., 2004). A simple stearic occlusion model seems unlikely however, 
if the primary binding site for MCM is the Cdt1 C-terminal domain but geminin binds the central 
domain. Nonetheless, geminin dimers bound to the Cdt1 central domain could conceivably 
project far enough towards the C-terminal domain to interfere with stable MCM binding. 
Alternatively, geminin binding may induce a conformational change in the Cdt1 central domain 
that propagates to the C-terminal domain. It may also be that Cdt1 forms multiple contacts with 
the MCM ring, and that geminin interferes with MCM binding sites in Cdt1 that are separate 
from those at the C-terminal Cdt1–Mcm6 interface (e.g., the diagram based on Sun et al. 2013 in 
Figure 1.2). Testing these ideas directly will ultimately require a structure including both the 
Cdt1 central and C-terminal domains with and without geminin. More ideas regarding geminin-
mediated inhibition of Cdt1 activity are found in Chapter 4 of this work: Conclusions and Future 
Directions. 
Cdt1 Phosphorylation 
Cdt1 is phosphorylated at many serine and threonine (but not tyrosine) sites at different 
times during the cell cycle and in response to different cues. Phosphoproteomic analyses have 
identified dozens of phosphorylation sites detectable in proliferating human cells. Figure 1.2 
marks only those human Cdt1 phosphorylation sites from the PhosphoSite Plus database 
(Hornbeck et al., 2015) that are conserved in at least one other mammalian Cdt1. Those marked 
in dark grey are Ser-Pro or Thr-Pro sites which conform to the minimal recognition sequence for 
both CDKs and MAP kinases (mitogen-activated protein kinases). The green symbols mark Ser-
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Pro and Thr-Pro sites that have been identified in proteomics screens and also tested for 
functional consequences. 
As discussed above (Section 4.2), phosphorylation at Thr29 targets Cdt1 for 
ubiquitylation by the CRL1Skp2 E3 ubiquitin ligase. Which kinase (or kinases) is most 
responsible for Thr29 phosphorylation? In vitro, Cdt1 can be phosphorylated by Cdk4 (activated 
in G1 by cyclin D), Cdk2 (activated in S by cyclin E and cyclin A) and Cdk1 (activated by cyclin 
A and cyclin B) (Liu et al., 2004; Sugimoto et al., 2004). Moreover, Cdt1 isolated from cell 
lysates co-precipitates cyclin A, but not cyclin E or cyclin B. CDK interaction depends on a 
cyclin binding motif known as a Cy motif in Cdt1 (aa 68–70) (Sugimoto et al., 2004). It is most 
likely that Thr29 phosphorylation to induce Cdt1 ubiquitylation by CRL1Skp2 is carried out by 
cyclin A/Cdk2 in early S phase, and Cdt1 phosphorylation in late S and G2 is carried out by 
cyclin A/Cdk1. 
Interestingly, Thr29 can also be phosphorylated in vitro by the MAP kinase, Jnk1 (Jun 
kinase) (Miotto and Struhl, 2011). Miotto and Struhl noted that treating cells to activate the stress 
kinase, Jnk1, also blocks Hbo1 recruitment to several selected origins (Miotto and Struhl, 2011). 
Mutating Thr29 enhanced Hbo1 residence at origins, suggesting that Jnk1-mediated Cdt1 
phosphorylation at Thr29 inhibits Hbo1 recruitment. Despite the ability of Jnk1 to phosphorylate 
Thr29, conditions that activate Jnk1 in cells (without causing DNA damage) had no effect on 
Cdt1 stability; the stability of Thr29-phosphorylated Cdt1 could indicate Jnk1-mediated 
inhibition of CRL1Skp2 or some other mechanism to prevent Cdt1 degradation (Miotto and Struhl, 
2008). In that study, the authors mapped multiple Cdt1 phosphorylation sites and determined 
which sites are sensitive to Jnk1 inhibitors. In addition to Thr29, at least two other 
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phosphorylation sites showed the same Jnk1-sensitive pattern as Thr29: Ser93 and Ser318, but 
the outcomes of these phosphorylations have yet to be determined (Miotto and Struhl, 2011).  
A concurrent study of Cdt1 phosphorylation by stress-activated MAP kinases focused on 
distinct sites in the linker domain and C-terminus. Chandrasekaran et al. mapped a collection of 
five sites that can be phosphorylated by either JNK or p38 MAPK isoforms: amino acids 372, 
402, 406, 411 and 491 (Figure 1.2) (Chandrasekaran et al., 2011). Functional tests of 
phosphomimetic substitutions at these five positions led to the inference that Cdt1 
phosphorylation not only inhibits its licensing activity in cells, but surprisingly, also blocks 
binding to the CRL4Cdt2 E3 ubiquitin ligase. As a result, this phospho-isoform of Cdt1 is resistant 
to degradation by CRL4Cdt2, though it is still sensitive to CRL1Skp2 (Takeda et al., 2005; 
Chandrasekaran et al., 2011). The molecular mechanism of licensing inhibition is not yet known, 
but the concentration of phosphorylation sites in the linker domain hints that phosphorylation 
could affect the positioning of the central and C-terminal domains relative to one another. 
Another possibility is that the N- and C-termini are in close proximity to each other to allow 
phosphorylation in the linker to disrupt CRL4Cdt2 binding to the PIP degron.  
Unlike Thr29 (and Ser31), these more C-terminally located phosphorylation positions are 
responsible for the commonly-observed mitotic Cdt1 gel mobility shift by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). This gel shift is evident not only in 
response to cellular stresses that activate p38 and JNK, but also during G2 and mitosis in 
unperturbed cell cycles and in quiescent cells (Nishitani et al., 2004; Chandrasekaran et al., 
2011; Varma et al., 2012; Coulombe et al., 2013). Cdt1 is robustly phosphorylated in mitotic 
cells and dephosphorylated in early G1, though the phosphatase responsible is not known. Both 
p38 and JNK are active during mitosis alongside Cdk1 (Thornton and Rincon, 2009). Since the 
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phosphorylation sites match the consensus sequence for both classes of proline-directed kinases, 
it is currently impossible to know which kinase(s) are truly responsible for Cdt1 mitotic 
phosphorylation. Regardless of how many kinases target these sites, the result is that beginning 
in late S phase, Cdt1 re-accumulates in a form that is not active for origin licensing and is no 
longer subject to rapid degradation (Figure 1.3). A potential role for geminin in Cdt1 protection 
from CRL1Skp2 during G2 has also been reported (Ballabeni et al., 2004; Tsunematsu et al., 
2013), but attempts to definitively confirm this relationship have utilized geminin and Cdt1 
manipulation which frequently induces DNA damage. Separating potential geminin-mediated 
direct effects on Cdt1 stability from established indirect effects related to re-replication 
dependent DNA damage (and subsequent CRL4Cdt2-mediated Cdt1 degradation) requires careful 
interpretation (Hall et al., 2008). Nonetheless, the Cdt1 stabilization in G2 may serve the dual 
purposes of allowing Cdt1 to function with the NDC80 complex at kinetochores and providing a 
large pool of Cdt1 in the subsequent G1 to license origins in the next cell cycle. 
Finally, the majority of detectable phosphorylation sites in human Cdt1 remain unstudied. 
Several of these match the consensus for CDK-mediated (or MAPK-mediated) phosphorylation. 
Are there additional CDK sites, and if so, are they dependent on the same Cy motif that directs 
phosphorylation at the N-terminus? Is there a MAPK docking site in Cdt1 that facilitates 
phosphorylation by p38 or JNK? The N-terminal PEST domain is in close proximity to several 
candidate sites which may function to inhibit Cdt1 chromatin binding in G2, though this idea has 
not been explicitly tested (Coulombe et al., 2013). Of further note, all of the consequences of 
phosphorylation thus far lead to Cdt1 inhibition or changes in stability. It remains equally 
possible that phosphorylation at one or more novel sites promotes Cdt1 function in either 
licensing or mitosis. 
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Cdt1 in Disease 
Although numerous mechanisms restrain Cdt1 function, pathological dysregulation of 
Cdt1 can still occur, particularly in cells whose control mechanisms have been compromised. 
Moreover, mutations in Cdt1 itself can cause pathological consequences.  
Overexpression and Oncogenesis 
Cdt1 overexpression can result in genotoxic stress leading to aberrant cell proliferation 
and predisposition to oncogenic transformation. Experimentally increased Cdt1 abundance 
outside of G1 phase promotes re-replication and genome instability (Vaziri et al., 2003; Seo et 
al., 2005; Fujita, 2006). Therefore, it is quite possible that more moderate overexpression from 
spontaneously deregulated transcriptional controls has the same effect on genome stability in 
vivo (Arentson et al., 2002; Petropoulou et al., 2008). Over time, higher-than-normal levels of 
Cdt1 protein may not be fully restrained during S phase and G2 by the ubiquitin ligases, kinases, 
and geminin inhibition described in Section 4. This means that at some low frequency, Cdt1 may 
promote origin re-licensing and re-replication. Interestingly, cells expressing higher than normal 
Cdt1 exhibit a more aggressive and chemoresistant phenotype (Galanos et al., 2016). In addition, 
the genome instability from Cdt1 likely includes not only gene amplification and chromosome 
damage from re-replication (Green et al., 2010), but also changes in chromosome number which 
may reflect Cdt1’s role in chromosome segregation (Arentson et al., 2002; Varma et al., 2012).  
Cdt1 transcription is driven by the E2F family of transcription factors (see Section 4.1), 
and one of the most frequently-mutated regulatory pathways in cancers is the Rb-E2F pathway 
(Dyson, 2016; Johnson et al., 2016). In fact, many cancer-derived cell lines exhibit higher-than-
normal expression of Cdt1 (Yoshida and Inoue, 2004). Cdt1 overexpression could also lead to 
rapid origin licensing and shorter G1, thus proliferate more rapidly but with less fidelity. To our 
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knowledge, a direct and quantitative correlation between Cdt1 abundance and the extent of 
genome instability in cancers has not yet been investigated. It may be that Cdt1 expression levels 
will identify particular cancers that are most likely to progress or are more or less susceptible to 
specific therapeutic interventions (Karavias et al., 2016).  
Meier-Gorlin Syndrome 
Avoiding either over- or under-licensing origins is critical for successful cell proliferation 
during development. The need for not only effective licensing inhibition after S phase but also 
efficient origin licensing in G1 is most apparent in the phenotypes associated with a rare 
primordial dwarfism syndrome, Meier-Gorlin Syndrome (MGS). MGS patients harbor 
hypomorphic mutations in genes encoding pre-RC components, including Cdt1, some ORC 
subunits, and Cdc6. These patients have extremely short stature, small external ears, and focal 
hypoplasias, likely due to slow cell proliferation (Bicknell et al., 2011a; Bicknell et al., 2011b; 
de Munnik et al., 2012). Furthermore, de novo mutations in the gene encoding geminin, have 
also been described in MGS patients (Burrage et al., 2015). In these instances, the mutations 
disrupt protein motifs required for normal geminin degradation in G1 phase (Burrage et al., 
2015). As a result, geminin could inappropriately inhibit Cdt1 and result in slow origin licensing 
and G1 delay. The Cdt1 MGS patient genotypes are compound heterozygous missense mutations 
combined with nonsense mutations (presumed null alleles) (Bicknell et al., 2011a; de Munnik et 
al., 2012). In addition, the CDT1 mutations are present across most of the CDT1 gene and 
translate to amino acid substitutions located in regions that are presumably important for Cdt1 
regulation and activity. Cdt1 is an essential gene, so these alleles are likely hypomorphic rather 
than null.  
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Although origin licensing defects appear to be one molecular underpinning of MGS, not 
all MGS patients have mutations in origin licensing components. Recently, hypomorphic 
mutations in the CDC45 gene that encodes one of the helicase activating subunits were identified 
in an additional cohort of MGS patients (Fenwick et al., 2016). Cdc45 is not required for origin 
licensing in G1, but rather it is required for origin firing and replication fork progression during 
S-phase as part of the fully-active helicase (Cdc45-MCM2-7-GINS). These CDC45 mutations 
result in splicing defects leading to a significant reduction in Cdc45 protein (Fenwick et al., 
2016). The change in Cdc45 protein abundance likely impairs DNA synthesis, thus hindering 
cell proliferation and genome stability in early development. 
Interestingly, the pre-RC proteins affected in MGS include Cdt1, Cdc6, and subunits of 
ORC, but not MCM subunits. Do mutations in MCM lead to MGS phenotypes? Analyses of a 
spontaneous mutation in the mouse Mcm4 subunit suggests that dwarfism is not a universal 
outcome of licensing disruption. In these studies, hypomorphic Mcm4 mutations resulted in mice 
with increased micronuclei (a sign of chromosome instability) and increased tumor incidence, 
but otherwise grew to normal size (Shima et al., 2007). Mouse embryonic fibroblasts from 
crosses between the hypomorphic and null alleles proliferate normally but are sensitive to 
replication stress (Shima et al., 2007). These findings are in contrast to cells bearing MGS alleles 
in other licensing proteins that proliferate slowly (Bicknell et al., 2011b; Guernsey et al., 2011). 
These differences could reflect the degree of impairment by the different mutations, or they 
could reflect qualitative differences in the roles of the altered proteins. Such complexity certainly 
creates challenges for predicting the precise phenotypes of any newly-identified Cdt1 mutations, 
but the general expectation is impaired cell proliferation and/or genome instability. 
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Summary 
Metazoan Cdt1 is regulated by a large number of independent mechanisms including 
inhibitor binding, phosphorylation, and ubiquitylation. It is likely that even more regulatory 
mechanisms will continue to be discovered, perhaps from follow-up studies to the proteomic 
detection of Cdt1 acetylation or sumoylation (Hornbeck et al., 2015). The need for such 
extensive regulation may be because Cdt1 is an integral player in both DNA replication and 
chromosome segregation, meaning Cdt1 deregulation has potent effects on genome stability and 
cell proliferation. The mitotic Cdt1 function clearly arose in eukaryotic evolution after the split 
between unicellular and multicellular species, so the presumed ancestral function was origin 
licensing.  
Why would Cdt1 evolve to have a role in kinetochore–microtubule attachment, a function 
that does not involve loading proteins onto DNA? It is becoming increasingly common to 
discover second cell cycle functions for origin licensing proteins, such as non-licensing roles for 
individual ORC subunits or geminin (Prasanth et al., 2002; Del Bene et al., 2004; Luo et al., 
2004; Prasanth et al., 2004; Hemerly et al., 2009; Yang et al., 2011). Perhaps it is generally 
useful to re-purpose proteins that are already under cell cycle-dependent control for a second cell 
cycle function. Alternatively, it may be that Cdt1 has biophysical properties that are uniquely 
suited to its molecular roles in both origin licensing and kinetochore–microtubule attachment. 
Based on our limited current knowledge, we can attempt to draw parallels between 
Cdt1’s two targets: the MCM and NDC80 complexes. In both cases, a multisubunit complex 
undergoes important conformational changes. For NDC80, the change manifests as a molecular 
extension in vivo, and for MCM it is the presumed opening and closing of the Mcm2–Mcm5 
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gate. It is thus tempting to speculate that Cdt1 stabilizes a particular (extended?) conformation in 
the MCM complex, and that its two cell cycle roles are in fact related. We look forward to future 
developments in the field that will continue to shed light on the regulation and function of this 
unique protein. 
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CHAPTER 2: CDT1 VARIANTS REVEAL UNANTICIPATED ASPECTS OF 
INTERACTIONS WITH CYCLIN/CDK AND MCM IMPORTANT FOR NORMAL 
GENOME REPLICATION2 
Introduction 
 DNA replication must be tightly regulated to ensure normal cell proliferation throughout 
development. DNA damage arising from errors in DNA replication can lead to oncogenic 
transformation, developmental disorders, and aging (Arentson et al., 2002; Blow and Gillespie, 
2008; Yekezare et al., 2013). The first essential DNA replication step is DNA helicase loading 
which occurs in G1 phase of the cell cycle through the nucleation of several protein components 
at presumptive replication origins. This process is known as “origin licensing.” DNA helicase 
loading renders origins competent for DNA replication in the subsequent S phase. Unscheduled 
origin licensing after G1 can lead to DNA re-replication, DNA damage, cell death, and genome 
instability (Vaziri et al., 2003; Melixetian et al., 2004; Li and Jin, 2010). For this reason, origin 
licensing is tightly restricted to G1 to ensure “once, and only once” genome duplication each cell 
cycle (Cook, 2009; Truong and Wu, 2011). On the other hand, insufficient licensing increases 
the probability of incomplete replication, another source of genome instability and proliferation 
failure (Shreeram et al., 2002; Machida et al., 2005; Nevis et al., 2009). To avoid incomplete 
replication, the length of G1 phase is influenced by the status of origin licensing in normal 
                                                          
2Modified from: Pozo, P.N., Matson, J.P., Cole, Y., Kedziora, K.M., Grant, G.D., Temple, B. and 
Cook, J.G. Cdt1 variants reveal unanticipated aspects of interactions with Cyclin/CDK and MCM 
important for normal genome replication. MBoC. 2018. In Press. Pozo, P.N. generated all of the 
data unless otherwise noted in the figure legends.   
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mammalian cells (Shreeram et al., 2002; Vaziri et al., 2003; Liu et al., 2009; Nevis et al., 2009; 
Matson et al., 2017). 
The Cdt1 (Cdc10-dependent transcript 1) protein is essential for origin licensing in 
eukaryotic cells. In coordination with ORC (Origin Recognition Complex) and Cdc6 (Cell 
division cycle 6), Cdt1 recruits and participates in loading the core of the replicative helicase 
MCM2-7 (Minichromosome Maintenance) at presumptive origins. Human Cdt1 licensing activity 
is restricted to G1 through combinations of transcriptional control, phosphorylation, ubiquitin-
mediated degradation, and binding to a specialized inhibitor protein, Geminin (Pozo and Cook, 
2016). Unlike the ORC, Cdc6, and MCM ATPases, Cdt1 is not an enzyme. Moreover, the Cdt1 
primary sequence is not as highly conserved among eukaryotic species as the other licensing 
factors, and the regulation of human Cdt1 is complex  (Fujita, 2006). This complexity 
presumably arose because loss of proper human  Cdt1 control is particularly genotoxic (Arentson 
et al., 2002; Liontos et al., 2007). Extensive biochemical assays of reconstituted yeast origin 
licensing reactions have demonstrated that Cdt1 is absolutely required for MCM loading (Evrin 
et al., 2009; Remus et al., 2009), but the precise role of Cdt1 remains relatively mysterious.  
We sought additional insight into Cdt1 function by analyzing the consequences of 
naturally occurring Cdt1 missense alleles. The first partial-loss-of function variant in a metazoan 
Cdt1 was described in Drosophila melanogaster (Whittaker et al., 2000). The orthologous 
vertebrate variants had low activity in vitro (De Marco et al., 2009; You et al., 2016), but the 
specific reason for the weak origin licensing activity was not determined. Importantly, several 
studies have found that inherited mutations in human origin licensing factors, including Cdt1, 
can result in developmental disorders (Bicknell et al., 2011a; Bicknell et al., 2011b; Burrage et 
al., 2015). Cdt1 mutations are one cause of a form of primordial dwarfism called Meier-Gorlin 
37 
 
Syndrome. Patients are extraordinarily short with microcephaly, focal hypoplasias, and some 
characteristic facial features and tissue-specific phenotypes (Bicknell et al., 2011a; de Munnik et 
al., 2012); these phenotypes are consistent with cell proliferation defects. Indeed, primary 
fibroblasts from Meier-Gorlin Syndrome patients proliferate slowly in culture (Bicknell et al., 
2011b). We hypothesized that each of these mutations perturbs at least one aspect of Cdt1 
regulation or function. Our analyses of these alleles identifies a previously unappreciated MCM 
binding site and separately, uncovers new features of Cyclin A-dependent Cdt1 control to 
prevent genotoxic re-replication. 
Results 
Comparative functional analysis of Cdt1 variants by re-replication induction. 
  Bicknell et al. reported eight Cdt1 alleles in Meier-Gorlin Syndrome patients (Bicknell et 
al., 2011a); we marked the positions of the amino acids affected by all missense alleles and one 
of the three nonsense alleles in Figure 2.1A. All of the dwarfism patient genotypes were 
compound heterozygotes, and the most common combinations were a missense allele plus a 
nonsense allele predicted to encode a truncated Cdt1 protein. We included all missense mutations 
in our study. In addition, we included Cdt1-Y520X because it encodes the longest of the 
predicted truncations, and we reasoned that if Cdt1-520X is null for function then the shorter 
truncations are also null. We added Cdt1-R210C, a variant first discovered as a D. melanogaster 
partial loss-of-function mutant (Whittaker et al., 2000). This analogous vertebrate variant has 
reduced origin licensing activity in vitro (De Marco et al., 2009; You et al., 2016), but the 
molecular mechanism of reduced activity is not known. We introduced each of these mutations 
into a vector encoding full length Cdt1 under control of a doxycycline-inducible promoter with a 
C-terminal extension that includes polyhistidine and HA epitope tags. We then generated  
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Figure 2.1. 
 
Figure 2.1. Functional analysis of Cdt1 variants by re-replication induction (A) Illustration 
of the relative location and amino acid substitution of the alleles chosen in this study; 
polyhistidine and HA epitope tags and relevant binding domains are also marked. (B) 
Immunoblot of inducible expression of stably-integrated HA-tagged WT Cdt1 in U2OS cells. 
Cells were grown in 0 µg/mL, 0.05 µg/mL, 0.1 µg/mL, and 1 µg/mL doxycycline (dox), 
respectively. (C) Analytical flow cytometry profiles of U2OS cells expressing vector, ectopic 
HA-tagged WT Cdt1, or the indicated HA-tagged Cdt1 variants. Cells were treated with 1 µg/mL 
dox for 72 hrs. and pulse labeled with EdU for 30 minutes prior to harvesting. An illustration of 
the gating scheme is also shown; “>4C DNA” are cells that have undergone DNA re-replication. 
(D) Immunoblots of Cdt1 expression from C. Light Exp. – light exposure; Dark Exp. – dark 
exposure. (E) The percentage of cells with >4C DNA content in at least 4 biological replicates. 
Bars represent mean and standard deviation. **** = p value < 0.0001; ** = p value <0.005; * = p 
value <0.05; n.s. = not significantly different. 
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derivatives of the U2OS osteosarcoma cell line by recombination of each expression construct 
into a chromosomal FRT site using Flp recombinase; the parent cell line constitutively expresses 
the Tet repressor (Malecki et al., 2006). Using this experimental approach, we achieved dose-
responsive inducible ectopic Cdt1 expression (Figure 2.1B).  
We first examined the effects of overexpressing each Cdt1 variant by high-dose 
doxycycline (dox) treatment. Cdt1 overexpression can induce DNA re-replication detectable as a  
population of cells with greater than the normal G2 phase DNA content (i.e. >4C) (Vaziri et al., 
2003). We measured re-replication by analytical flow cytometric analysis after overproducing 
Cdt1-WT (wild type) or Cdt1 variants in asynchronously proliferating cultures for 72 hrs (Figure 
2.1C, D). We scored the percent of cells with >4C DNA content in multiple independent 
experiments (Figure 2.1E). Of note, Cdt1 overexpression to this degree had modest effects on 
the cell cycle distributions among G1, S, and G2/M phases (Figure 2.2). The more extensive the 
re-replication, the greater the down-regulation of endogenous Cdt1 which we had previously 
linked to Cul4-dependent Cdt1 degradation (for example Figure 2.1D, endogenous Cdt1 in lanes 
7, 8) (Hall et al., 2008).  
After multiple independent tests, we noted that Q117H, R210C, and R453W had re-
replication-inducing activity similar to WT, whereas R462Q and E468K were less active by this 
metric (Figure 2.1E). Y520X failed to accumulate to high levels at any doxycycline 
concentration (Figure 2.1D, lane 5 and data not shown) which may indicate impaired protein 
folding and by extension, that all truncation alleles are likely null for Cdt1 biological activity. 
Given the proliferation defect associated with Meier-Gorlin Syndrome, we anticipated that most 
alleles encode partial loss-of-function variants like R462Q and E468K. Surprisingly however, 
the A66T dwarfism variant consistently induced nearly four-fold more re-replication than Cdt1- 
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Figure 2.2. 
 
 
Figure 2.2. Stacked bar graphs of cell cycle phase distribution of cells overproducing WT 
or variant Cdt1 from Figure 2.1. The percentage of U2OS cells in each cell cycle phase and 
percentage of re-replicating cells from at least three biological replicates is graphed. Bars 
represent mean with error ± SD. 
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WT did (Figure 2.1C, E), even when produced to similar levels (Figure 2.1D), indicating that it 
is a gain-of-function allele. We focused our subsequent analyses on the subset of mutations with 
detectable effects on Cdt1 activity in vivo, i.e. A66T, R462Q, E468K (Figure 2.1C, E), and 
R210C (Whittaker et al., 2000; De Marco et al., 2009; You et al., 2016). 
Given that DNA re-replication is associated with DNA damage and genomic stress, we 
assessed Cdt1-overproducing cells for activation of the DNA-damage response. We analyzed the 
activating Chk1 phosphorylation at S345 as a marker of replication stress and DNA damage 48 
hrs. after initiating Cdt1 overproduction (Figure 2.3A, B). As expected (Vaziri et al., 2003; 
Davidson et al., 2006; Hall et al., 2008), Cdt1-WT overexpression induced Chk1 
phosphorylation that correlated with the degree of re-replication induced by the different Cdt1 
variants (Figure 2.3B). Of particular note, Cdt1-A66T induced significantly more re-replication 
and Chk1 activation than Cdt1-WT or Cdt1-R210C did, whereas Cdt1-R462Q and Cdt1-E468K 
induced significantly less re-replication and Chk1 activation than Cdt1-WT did (Figure 2.3A, 
B).  
Extensive re-replication, replication stress, and DNA damage can impair cell proliferation 
(Li and Jin, 2010; Truong and Wu, 2011). As a measure of the ability of each of the Cdt1 
variants to impact proliferation, we plated each cell line in either high doxycycline or no 
doxycycline as a control and assessed colony-formation over 10 days. Cdt1-WT overexpression 
strongly blocked colony formation (Figure 2.3C, D). There was general correlation among the 
variants of the degree of re-replication and DNA damage response with the degree of toxicity 
induced by Cdt1 overproduction in the colony forming assay (Figure 2.3D). In particular, A66T 
which was hyperactive for re-replication was even more toxic than WT Cdt1 in this assay 
(Figure 2.3D).  
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Figure 2.3. 
 
 
 
 
Figure 2.3. DNA damage and cell proliferation defects from Cdt1 variant overproduction* 
(A) Immunoblot of HA-tagged Cdt1 (anti-HA antibody), pChk1 (S345) and total Chk1 in U2OS 
cells grown in 1 µg/mL dox for 48 hours. (B) Graph of pChk1 (S345) induction normalized to 
WT Cdt1. Bars represent mean and standard deviation of three biological replicates. **** = p 
value <0.0001; * = p value <0.05; n.s. = not significantly different. (C, top) Representative 
vector and WT Cdt1 control colony forming assays. Cells were plated at low density in the 
presence or absence of 1 µg/mL doxycycline (dox) and grown for ~10 days. (C, bottom) A 
technical replicate plate was harvested after 72 hours to assay for ectopic Cdt1 expression by 
immunoblotting with anti-Cdt1 antibody. (D) Relative colony formation normalized within each 
experiment to the vector control; values represent at least three biological replicates. Bars 
represent mean and standard deviation. ** = p value <0.005; n.s. = not significantly different. 
*Cole, Y. generated data in this figure. 
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Comparative functional analysis of MCM loading.  
 
Given that most Meier-Gorlin mutations affect genes encoding essential origin licensing 
proteins (Cdt1, Cdc6, ORC, etc.), we hypothesized that the defects associated with Cdt1 
hypomorphic variants are primarily related to MCM loading. To test this idea directly, we 
induced expression of the Cdt1 variants in asynchronously growing cells with low doxycycline 
to approximately match endogenous Cdt1 levels. We simultaneously depleted endogenous Cdt1 
using an siRNA; the ectopic Cdt1 expression constructs bear synonymous mutations at the 
siRNA binding site and are thus resistant to depletion (Figure 2.4D). We then pulse labeled the 
cells with EdU for 30 minutes prior to harvesting and extracted cells to release soluble MCM 
complexes, followed by fixation to retain loaded MCM complexes. We probed the extracted 
cells for Mcm2 as a marker of the MCM2-7 complex, stained for total DNA content, detected 
EdU incorporation, and analyzed the samples by flow cytometry (see Materials and Methods). 
We previously validated this assay for quantifying MCM loading rates in asynchronously 
proliferating individual cells (Matson et al., 2017). Figure 2.4A shows flow cytometry profiles 
of extracted cells with chromatin-bound MCM on the y-axis and DNA content on the x-axis. 
MCMBound-positive/ EdU-negative G1 cells are shown in blue, MCMBound-positive/ EdU-positive 
cells are shown in orange, and MCMBound-negative/ EdU-negative cells are shown in grey. Using 
these analytical flow cytometry profiles, we isolated the G1 phase MCM positive cells in silico 
and plotted these data in histogram form as a measure of licensing activity (Figure 2.4B). In 
previous work, we demonstrated that these histograms reveal both the total amount of MCM 
loaded per cell, and the rate of MCM loading within G1 phase (Matson et al., 2017).  
As expected, Cdt1 depletion without ectopic Cdt1 expression resulted in defective MCM 
chromatin loading in G1 (Figure 2.4B, green trace), but expression of the epitope-tagged Cdt1- 
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Figure 2.4. 
 
Figure 2.4. Functional analysis of MCM loading* (A) Analytical flow cytometry profiles of 
chromatin bound MCM in U2OS cells treated with 100 nM control siRNA (left) or Cdt1 siRNA 
(right). Cells were pulse labeled with 10 µM EdU for 30 minutes prior to harvesting and 
extraction of soluble MCM. Bound (unextracted) MCM was detected with anti-MCM2 antibody, 
and cells were stained with DAPI for total DNA content. Blue: MCMBound positive, EdU 
negative, G1 DNA content, Orange: EdU positive, MCMBound positive, Grey: EdU negative and 
MCMBound negative. (B) Histograms of the G1 MCMBound positive, EdU negative (i.e. blue in A) 
cells from both samples in A. Bound MCM on the x-axis and normalized cell counts on the y-
axis (counts normalized to siControl). (C) Histograms of G1 MCMBound positive cells depleted of 
endogenous Cdt1 and expressing each Cdt1 variant compared to WT Cdt1 as in B. siRNA 
transfected cells were cultured in 0.002-0.006 µg/ml doxycycline for 72 hrs. prior to EdU 
labeling and processing as in A. (D) Immunoblot of endogenous and ectopic Cdt1 from C 
detected with anti-Cdt1 antibody. (E) Complementation of G1(green/blue) and early S (orange) 
MCM loading normalized to WT Cdt1. Mean MCMBound loading intensity of each variant was 
divided by the mean MCM loading intensity of WT Cdt1 within each experiment. Early S phase 
is defined as G1 DNA content and EdU-positive indicated by the bracket in A; see also Figure 
2.6B. Bars represent mean and standard deviation of three biological replicates. * = p value 
<0.05; ** = p value <0.005 where indicated, otherwise the difference between WT Cdt1 and 
variant was not significantly different. *Matson, J.P. generated data in this figure. 
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WT complemented this MCM loading defect (Figure 2.4C, compare grey and green traces). 
We quantified the G1 origin licensing dynamics for multiple replicates and plotted the average 
amount of MCM loaded in G1 relative to Cdt1-WT controls in Figure 2.4E (green dots for 
vector and blue dots for cells expressing ectopic Cdt1). By this measure, the R462Q and E468K 
variants were significantly impaired for MCM loading in G1 (Figure 2.4C, E, blue traces and 
blue dots). Strikingly, the R210C variant was also significantly impaired for MCM loading even 
when it accumulated to higher levels than Cdt1-WT (Figure 2.4C, D lane 6, E). Based on these 
complementation assays, we interpret the relative activity of the hypomorphs as R462Q =E468K 
> R210C (i.e. Cdt1-R210C is the weakest for G1 MCM loading when expressed at normal 
levels) whereas R210C is more active for inducing re-replication than R462Q and E468K when 
overproduced (Figure 2.1).  
Unlike the hypomorphic alleles, Cdt1-A66T showed no MCM loading defect in G1, 
which is consistent with the idea that this variant is not a loss-of-function allele (Figure 2.4C 
and E). Interestingly, cells expressing Cdt1-A66T re-replicated more than Cdt1-WT expressing 
cells even at expression levels that were as low as endogenous Cdt1 (Figure 2.4D; Figure 2.5B). 
These results suggest that Cdt1-A66T hyperactivity does not require artificial overproduction. 
The defects in origin licensing exhibited by the hypomorphic variants prompted us to ask 
if these cells enter S phase with underlicensed chromosomes. To directly determine if these cells 
routinely enter S phase with lower amounts of MCM loading, we isolated the early S phase cells 
(Figure 2.4A) in silico from the analytical flow cytometry profiles (Figure 2.6) and quantified 
the amount of MCM loaded in early S for each variant (Figure 2.4E, orange squares). 
Interestingly, cells expressing the hypomorphic variants entered S phase with similar amounts of 
loaded MCM as cells expressing WT Cdt1 (Figure 2.4E, orange squares). Moreover, a  
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Figure 2.5. 
 
Figure 2.5. Change in population doubling times and cell cycle phase distributions of cells 
expressing WT or variant Cdt1 used in complementation experiments.* (A) The change in 
doubling time was calculated by dividing the doubling time of siRNA + doxycycline treated-
cells by the doubling time of the corresponding untreated U2OS cells. A doubling time value of 
1 signifies no change in doubling time. Bars represent mean with error ± SD. * = p value <0.05 
where indicated, otherwise differences between WT Cdt1 and the variants was not significantly 
different. (B) Stacked bar graphs of cell cycle distribution of U2OS cells from Figure 2.4. The 
percentage of cells in each cell cycle phase and percentage of re-replicating cells from at least 
three biological replicates are graphed. Bars represent mean with error ± SD. * = p value <0.05 
where indicated, otherwise differences between WT Cdt1 and the variants was not significantly 
different. *Matson, J.P. generated data in this figure. 
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Figure 2.6. 
 
Figure 2.6. Analytical flow cytometry profiles of siRNA-treated cells used for MCM 
binding analysis in Figure 3.* (A) Cells were treated with 100 nM siRNA for 72 hours in 0.002 
µg/mL – 0.006 µg/mL doxycycline then labeled with EdU for 30 minutes prior to harvesting and 
extraction of soluble MCM. Samples were stained with anti-MCM2 antibody and DAPI to 
measure chromatin-bound MCM and overall DNA content, respectively. (B) Representative 
example (Vector plus siControl) treated as in A showing the gating scheme used to quantify 
chromatin-bound MCM specifically in early S phase. *Matson, J.P. generated data in this figure. 
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consequence of underlicensed S phase is hypersensitivity to replication stress (Woodward et al., 
2006; Blow et al., 2011; McIntosh and Blow, 2012), but cells depleted of endogenous Cdt1 and 
expressing the hypomorphic variants showed no hypersensitivity to low doses of hydroxyurea (a 
source of exogenous replication stress) compared to controls (data not shown).  We noted 
however that these cells did proliferate a little more slowly over just a 3-day time course (Figure 
2.5A). Instead of entering S phase with too little MCM loaded, cells expressing hypomorphic 
Cdt1 variants spent slightly more time in G1 phase compared to cells expressing WT Cdt1 
(Figure 2.5). Together, these results suggest that the slower MCM loading in G1 can delay S 
phase entry due to the activity of a previously-documented origin licensing checkpoint 
(Shreeram et al., 2002; Liu et al., 2009; Nevis et al., 2009). The outcome is that most cells enter 
S with sufficiently licensed chromosome to complete a normal S phase, but the cell population 
proliferates more slowly.   
Comparative analysis of MCM binding  
 
We considered that the functional effects of Cdt1 mutations may be linked to key protein-
protein interactions, specifically Cdt1-MCM binding. To test this notion, we immunoprecipitated 
WT or variant Cdt1 using the HA epitope tag and probed for MCM2-7 interaction using Mcm2 as 
a marker of the complex. Previous studies have mapped the Cdt1-MCM binding domain to a C-
terminal region, and some mutations in this domain of metazoan Cdt1 impair binding to a partial 
MCM complex (Ferenbach et al., 2005; Jee et al., 2010). It was not surprising then that Cdt1-
A66T, which is located near the N-terminus of Cdt1 and not the C-terminal domain, bound 
MCM as well as WT Cdt1 did (Figure 2.7A). Also consistent with prior studies of the Cdt1-
MCM interaction, the two hypomorphic variants located in the C-terminal domain of Cdt1, Cdt1-
R462Q and Cdt1-E468K, were consistently impaired for MCM binding (Figure 2.7B, C). On the  
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Figure 2.7. 
 
Figure 2.7. Relative MCM binding* (A-D) WT and the indicated Cdt1 variants were 
transiently expressed in HEK 293T cells and immunoprecipitated using the HA epitope tag. 
Portions (2%) of whole cell lysates and bound proteins were probed for HA-Cdt1 (anti-HA 
antibody) and for MCM2 as a marker of the MCM complex; IgG or beads were used as controls 
(CTRL). (E, top) Homology model of the human MCM2-7-Cdt1 complex. The yeast OCCM 
structure (PDB ID: 5UDB) was used as a template to model the human MCM2-7 complex; 
numbers indicate individual MCM subunits, and colors are similar to Yuan et al.. The structure 
of the human C-terminal Cdt1 winged helix, “Cdt1-CTD” (PDB ID: 2WVR) and mouse Cdt1 
central/middle domain “Cdt1-MD” (PDB ID: 3A4C) were used to model hCdt1-hMCM 
interactions. (E, bottom left) Magnified view of the proposed interacting surfaces with R210 
highlighted in green. (E, bottom right) Magnified view of the proposed interacting surfaces with 
R462 and E468 highlighted in green. *Temple, B. generated the structural data in this figure. 
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other hand, Cdt1-R210 is located in the middle domain of Cdt1 and not in the previously 
described Cdt1-MCM binding domain. It was thus unexpected that, like Cdt1-R462Q and Cdt1-
E468K, Cdt1-R210C was also impaired for MCM interaction (Figure 2.7D). This result suggests 
the existence of an MCM binding domain in Cdt1 distinct from the C-terminal domain.  
Structures of budding yeast Cdt1 in complex with other licensing proteins have recently 
been reported, and although two domains of mammalian Cdt1 orthologs have been structurally 
characterized (Frigola et al., 2017; Yuan et al., 2017; Zhai et al., 2017), there is no complete 
structure of metazoan Cdt1 available. Therefore, to visualize the locations of these mutations 
relative to the human MCM2-7 complex, we generated a homology model using publicly 
available crystal, cryo-EM, and NMR structures of Cdt1-MCM2-7 complexes. We derived our 
model using the recent cryo-EM yeast ORC1-6-Cdc6-Cdt1-MCM2-7 (OCCM) complex (Yuan et 
al., 2017) as a template for modeling the human MCM complex (see Materials and Methods). 
We superimposed structures for the human Cdt1 C-terminal domain (De Marco et al., 2009) and 
mouse C-terminal (Khayrutdinov et al., 2009) on the OCCM structure to model the mammalian 
Cdt1-MCM2-7 interaction (Figure 2.7E, top).  The Cdt1 C-terminal domain adopts a winged 
helix fold of the type predicted to mediated protein-protein rather than protein-DNA interactions 
(Khayrutdinov et al., 2009). In this model, residues R462 and E468 are at the interface between 
the Cdt1 C-terminal domain and the Mcm6 subunit of the MCM2-7 heterohexamer (Figure 2.7E, 
bottom right). Mutating these residues likely disrupts the binding surface between Cdt1 and 
Mcm6 resulting in defective Cdt1-MCM interactions.  
We also consistently observed weak binding between Cdt1-R210C and MCM (Figure 
2.7D), but Cdt1 R210 is not in the C-terminal MCM binding domain. Our homology model 
positions this residue near the Mcm2 subunit of the MCM2-7 heterohexamer (Figure 2.7E, 
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bottom left). This proposed interface is distinct from the suggested interface between the Cdt1 
C-terminal domain and Mcm6. In addition, cryo-EM structures of the yeast Cdt1-MCM2-7 
complex predict multiple contact points between Cdt1 and the MCM2-7 complex (Sun et al., 
2013; Yuan et al., 2017). The functional defects of Cdt1-R210C, Cdt1-R462Q, and Cdt1-E468K 
in cells support the notion that Cdt1 requires multiple binding interfaces with the MCM2-7 
complex. Our functional and binding analysis suggests that disrupting either of these interfaces is 
sufficient to impair both MCM2-7 binding and MCM2-7 loading. We note that this domain, rather 
than the C-terminal domain is the primary site of Cdt1 interaction with its inhibitor, geminin 
(Lee et al., 2004) (Ferenbach et al., 2005; Jee et al., 2010). 
Cdt1-A66T impairs Cyclin A and Skp2 binding but does not stabilize Cdt1 in S phase.  
 
The unexpected gain-of-function phenotype of the A66T dwarfism-associated variant 
prompted us to explore this variant in more detail. Cdt1 A66 is just N-terminal to a previously 
identified negative-regulatory domain in Cdt1 (Coulombe et al., 2013) and very close to the 
well-defined Cyclin/CDK binding motif (“Cy motif”) at positions 68-70. Based on the close 
proximity, we hypothesized that A66T perturbs the Cdt1-Cyclin/CDK interaction (Figure 2.8A). 
To test this idea, we isolated Cdt1-A66T, Cdt1-WT, and Cdt1-Cy, a bona fide mutational 
disruption in the Cy motif (alanines at positions 68, 69, and 70) from cell lysates using the C-
terminal tag and probed the complexes for Cyclin A; previous studies identified Cyclin A as the 
primary cyclin that interacts with the Cdt1 Cy motif (Sugimoto et al., 2004). Cdt1-WT bound 
Cyclin A by this assay, but the Cy motif mutant did not (Figure 2.8B). Interestingly, Cdt1-A66T 
bound Cyclin A very poorly relative to Cdt1-WT and only slightly better than the Cy motif 
mutant (Figure 2.8B, compare lane 7 to lanes 6 and 8).  
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Figure 2.8. 
 
Figure 2.8. Cdt1-A66T impairs Cyclin A and Skp2 binding but does not stabilize Cdt1 in S 
phase* (A) Illustration of SCFSkp2-dependent degradation of WT Cdt1 via CDK-mediated 
phosphorylation at threonine 29. (B) Cells were cultured in 1 µg/mL doxycycline (high) for 18 
hrs., lysed, and incubated with nickel-agarose to retrieve His-tagged Cdt1. Portions of whole cell 
lysates (2%) and bound complexes were probed for the indicated proteins (bottom panel anti-HA 
antibody). (C, top) Illustration of Cdt1 degradation and accumulation during the cell cycle. (C, 
bottom) U2OS cells expressing Cdt1-WT and Cdt1-A66T were synchronized by double-
thymidine/nocodazole (lanes 1-5) or double-thymidine (lanes 6-10) block and released into fresh 
medium. Time points were taken after release and analyzed by immunoblotting with anti-Cdt1 
antibody. a non-specific band serves as a loading control. (D) The intensity of WT or A66T 
Cdt1-Venus expressed in U2OS cells imaged during asynchronous proliferation every 10 
minutes. Traces are the average Venus intensity in arbitrary units from mitosis (0%) to mitosis 
(100% cell cycle progression); n= 50 cells. White circles denote the beginning and end of S 
phase as determined by the localization of stably co-expressed fluorescently tagged PCNA. (E) 
Heat map of fluorescence intensity of Cdt1 WT-Venus (left) and Cdt1-A66T- Venus (right) in 50 
randomly selected U2OS cells. Maps from individual cells are arranged according to the duration 
of the cell cycles, colors indicate differences in fluorescence levels. White dots in each track 
denote the beginning and end of S phase as determined by the localization of stably co-expressed 
fluorescently tagged PCNA. * Kedziora, K.M. and Grant, G.D. generated the live-cell imaging 
data in this figure. 
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The consequences of Cyclin A binding to Cdt1 have been linked to CDK-mediated Cdt1 
phosphorylation at T29. Cdt1 phosphorylation at T29 creates a binding site for the Skp2 
substrate adapter of the SCF E3 ubiquitin ligase, SCFSkp2 (Figure 2.8A) (Takeda et al., 2005). 
We therefore tested if the weak Cyclin A binding by Cdt1-A66T also resulted in weak Skp2 
binding; indeed, Cdt1-A66T bound very poorly to Skp2 compared to Cdt1-WT and slightly 
better than the Cdt1-Cy variant (Figure 2.8B, lanes 6-8). For this reason, we tested the stability 
of Cdt1-A66T relative to Cdt1-WT during S phase. We synchronized cells in mitosis and 
released them to progress from G1 into S phase taking time points until mid-S. We also blocked 
cells in early S phase and released them to progress into G2, then monitored endogenous and 
ectopic Cdt1 by immunoblotting. We found no detectable differences between Cdt1-A66T and 
Cdt1-WT or endogenous Cdt1 for degradation in early S or for Cdt1 re-accumulation as S phase 
ends (Figure 2.8C). SCFSkp2-mediated Cdt1 ubiquitylation cooperates with a second E3 
ubiquitin ligase, CRL4Cdt2, to destroy Cdt1 during S phase (Abbas and Dutta, 2011; Havens and 
Walter, 2011) (Figure 2.8C illustration), and this targeting does not require CDK-mediated 
Cdt1 phosphorylation (Arias and Walter, 2005). CRL4Cdt2 ubiquitylates Cdt1 in both S phase and 
after DNA damage (Arias and Walter, 2006; Jin et al., 2006; Havens and Walter, 2009). We 
observed no effect of the A66T mutation on Cdt1 degradation after UV irradiation (Figure 2.9), 
thus the change has no effect on CRL4Cdt2 targeting. 
Nonetheless, we considered that Cdt1-A66T could be slightly more stable at specific cell 
cycle times or in other settings in a manner that increases the likelihood of origin re-licensing 
and subsequent re-replication. We therefore added a C-terminal fluorescent tag to both Cdt1-WT 
and Cdt1-A66T (Figure 2.10) and carried out live cell imaging of asynchronously proliferating 
U2OS cells after doxycycline-induced expression. We tracked individual cells with similar  
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Figure 2.9. 
 
 
 
 
 
Figure 2.9. Cdt1-A66T variant is targeted for CRL4Cdt2-dependent degradation. U2OS cells 
were treated with 100 µg/mL doxycycline for 16 hours to induce ectopic expression of Cdt1-
WT-mVenus and Cdt1-A66T-mVenus. Cells were then subjected to 20 J/m2 UV and harvested 
at the indicated time points post-irradiation for subsequent immunoblot analysis with anti-Cdt1 
antibody. A non-specific band serves as loading control. 
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Figure 2.10. 
 
 
 
Figure 2.10. Cdt1 WT- and A66T-mVenus dynamics in asynchronously proliferating cells.* 
(A) Selected images from a typical time lapse experiment showing progression through the cell 
cycle of a U2OS cell expressing Cdt1 WT-Venus (upper rows) and Cdt1 A66T-Venus (lower 
rows). Cells stably co-expressed PCNA-mCherry. Division into cell cycle phases (G1, S, G2+M) 
was based on the variance of PCNA distribution as indicated by the red box; scale bar 10 µm. 
(B) Quantification of Cdt1 WT and A66T Venus intensities in different cell cycle phases (n=70 
Cdt1 WT and n=110 A66T, error bars are s.e.m.). No significant differences were observed 
between populations according to Wilcoxon rank sum test. (C) Distribution of durations of cell 
cycle phases in populations expressing Cdt1 WT and A66T. Black lines indicate the mean. (D) 
Representative anti-Cdt1 immunoblot of U2OS cells treated with 5 µg/mL doxycycline (lanes 2 
and 5) and 10 µg/mL doxycycline (lanes 3 and 6) for 72 hours. A non-specific band serves as a 
loading control. * Kedziora, K.M. and Grant, G.D. generated the live-cell imaging data in this 
figure. 
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maximum fluorescence intensities for both Cdt1-WT and Cdt1-A66T and plotted both the mean 
(Figure 2.8D) and the intensity values of 50 individual proliferating cells (Figure 2.8E). 
Importantly, we observed no statistically significant differences in the dynamics of Cdt1 
degradation and re-accumulation during the cell cycle for those cells that successfully divided. 
Moreover those A66T-expressing cells that arrested with large nuclei (presumably from re-
replication (Melixetian et al., 2004)) had normal degradation and accumulation in the S phase 
prior to the arrest (data not shown).  
Cdt1-A66T is largely impaired for SCFSkp2 binding, but there were no detectable 
consequences for Cdt1 stability since Cdt1-A66T levels are still subject to CRL4Cdt2 control. 
Nonetheless, Cdt1-A66T is a potent re-replication inducer. We thus considered that the mutation 
has consequences for Cdt1 activity beyond phosphorylation at T29. To test that idea directly, we 
expressed a Cdt1 phosphorylation site mutant in which T29 is converted to unphosphorylatable 
alanine. Cdt1 is also phosphorylated at S31 (Hornbeck et al., 2015), and although this 
phosphorylation has minimal impact on Skp2 binding compared to T29 phosphorylation (Takeda 
et al., 2005), we also converted S31 to alanine to avoid possible compensatory effects at this 
position; this double alanine mutant is “Cdt1-2A.” If the primary effect of Cdt1-A66T is to 
prevent phosphorylation at T29 (and S31), then we predicted that the phenotypes of cells 
overexpressing Cdt1-A66T, the Cdt1-Cy motif mutant, and Cdt1-2A should be similar, since 
each alteration blocks CDK-mediated T29 phosphorylation. We compared the DNA re-
replication activity induced by overproducing each of these Cdt1 variants. Strikingly both Cdt1-
A66T and Cdt1-Cy induced significantly more re-replication than Cdt1-2A did (Figure 2.11A, 
B). In these longer-expression experiments, Cdt1-Cy accumulates to higher levels than WT 
(Figure 2.11C), though we note that in shorter experiments such as in Figure 2.8B, Cdt1-Cy  
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Figure 2.11. 
 
 
 
Figure 2.11. CDK-Cdt1 binding suppresses re-replication independently of the Cdt1 
phosphodegron (A) Analytical flow cytometry profiles of cells treated with 1 µg/mL 
doxycycline for 48 hrs. and analyzed as in Figure 2.1. Cy: Cyclin/CDK binding motif mutant; 
2A: Cdt1 T29A, S31A. (B) The percentage of cells with >4C DNA content in at least 3 
biological replicates. Bars represent mean and standard deviation. * = p value <0.05; n.s. = not 
significantly different. (C) HA-tagged Cdt1 was detected by immunoblotting whole cell lysates 
from A with anti-Cdt1 antibody; a non-specific band serves as a loading control; Vec. = Vector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
58 
 
levels are similar to Cdt1-WT and Cdt1-A66T. This hyper-accumulation may be a consequence 
of cell cycle phase distribution from long-term expression (Figure 2.12) and/or of the apparent 
complete defect in SCFSkp2 binding. Nonetheless, Cdt1-A66T and Cdt1-2A routinely accumulate 
to similar levels (Figure 2.11C, compare lanes 3 and 5), yet Cdt1-A66T induces significantly 
more re-replication than Cdt1-2A does (Figure 2.11A, B). We thus conclude that Cdt1-A66T 
disrupts Cyclin A binding as a near-mimic of the engineered Cdt1-Cy motif mutant, and that 
Cyclin A binding to Cdt1 negatively regulates Cdt1 function by at least one mechanism that is 
independent of simply creating a phosphodegron for the SCFSkp2 E3 ubiquitin ligase. 
Discussion 
In this study, we analyzed naturally arising mutations in Cdt1 and demonstrate that hypo- 
and hypermorphic variants cause defects in cell proliferation through distinct molecular 
mechanisms. Specifically, Cdt1 mutations found in humans afflicted with Meier-Gorlin 
syndrome result in either Cdt1-MCM binding or Cyclin/CDK binding defects. Both of these 
scenarios can lead to proliferation defects from either changes in cell cycle length or problems in 
DNA replication control attributed to perturbed Cdt1 activity (Figure 2.13).  
Hypomorphic Alleles 
 
Meier-Gorlin (MG) syndrome is a form of primordial dwarfism characterized by growth 
retardation beginning in utero and continuing throughout adolescence. Based on the patient 
phenotypes, we hypothesized that all MG Cdt1 alleles are hypomorphic. Indeed, two of the 
alleles analyzed here, including Cdt1-R462Q which was present in most of the MG patients with 
Cdt1 mutations reported thus far, are hypomorphic for Cdt1 function (Bicknell et al., 2011a; 
Bicknell et al., 2011b; Guernsey et al., 2011; de Munnik et al., 2012). Q117 is poorly conserved  
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Figure 2.12. 
 
Figure 2.12. Stacked bar graphs of cell cycle distribution of U2OS cells overproducing WT 
or variant Cdt1 from Figure 2.11. The percentage of cells in each cell cycle phase and 
percentage of re-replicating cells from at least three biological replicates is graphed. Bars 
represent mean with error ± SD. 
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Figure 2.13. 
 
 
Figure 2.13. Model of cell proliferation defects from both hypomorphic or hypermorphic 
Cdt1 variants (A) WT Cdt1 supports normal MCM loading/origin licensing and normal DNA 
replication in S phase. (B) The A66T variant is impaired for CDK-mediated repression resulting 
in re-licensing and re-replication. The R210C, R462Q, and E468K variants are impaired for 
MCM2-7 binding in G1 phase leading to slow origin licensing and thus delayed G1 progression. 
Both scenarios ultimately lead to proliferation defects. 
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among Cdt1 sequences suggesting that it is not critical for Cdt1 function. Based on its apparently 
normal ability to induce re-replication and the poor conservation of Q117, we infer that Cdt1-
Q117H is hypomorphic for Cdt1 expression in the MG patient rather than function – possibly 
from inefficient mRNA splicing (Bicknell et al., 2011a). The mutation may reduce overall Cdt1 
expression in vivo rather than impact Cdt1 activity per se. R453 is buried in the winged-helix 
domain core of the human Cdt1 C-terminal domain (Khayrutdinov et al., 2009; Jee et al., 2010). 
Introducing a bulky aromatic tryptophan may globally disrupt folding rather than alter Cdt1 
interactions or function.  
The two functionally hypomorphic MG alleles in this study, Cdt1-R462Q and Cdt1-
E468K, encode substitutions of conserved solvent-exposed amino acids in the C-terminal Cdt1 
winged helix domain (Khayrutdinov et al., 2009; Jee et al., 2010). By analytical flow cytometry, 
we found that these variants support slower MCM loading relative to WT Cdt1. The 
hypomorphic nature of these alleles induce slow proliferation through a modest increase in cell 
cycle length (Figure 2.5A). Furthermore, our homology model places R462 and E468 at the 
interface between the Cdt1 C-terminal domain and the Mcm6 subunit of the MCM2-7 
heterohexamer, close to the Mcm6-Mcm4 interface. Thus, mutations in this region 
understandably impair MCM binding. 
Cdt1-R210C is orthologous to a mutation in the Drosophila melanogaster Cdt1 gene, 
Double-Parked (Dup). Whittaker et al. characterized this variant as hypomorphic resulting in 
DNA replication defects and female sterility (Whittaker et al., 2000). Previous studies reported 
that this Cdt1 variant supported less DNA synthesis in vitro (De Marco et al., 2009), and had a 
modest effect on migration of a Cdt1-MCM2-7 complex by native gel electrophoresis (You et al., 
2016). We found that this variant has impaired Cdt1-MCM2-7 binding by co-immunoprecipitation 
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from human cell lysates. This variant supports slow origin licensing that is nearly as slow as the 
two dwarfism hypomorphic alleles in the C-terminal domain. The similarity in both cellular and 
molecular phenotypes of Cdt1-R462Q, Cdt1-E468K, and Cdt1-R210C suggests that both the 
central domain and C-terminal domain are equally important for Cdt1-MCM binding. 
Jee et al. suggested the existence of cooperation between the central domain of Cdt1 and 
the C-terminal domain in origin licensing (Jee et al., 2010). Yanagi et al. found that a fragment 
of murine Cdt1 including the central domain but lacking the Cdt1 C-terminal domain can 
associate with a subcomplex of three subunits, MCM4/6/7 (Yanagi et al., 2002). The notion of 
multiple contacts between Cdt1 and MCM2-7 is consistent with recent structural and functional 
analysis of yeast Cdt1-MCM2-7 in which Cdt1 serves as a brace to keep the MCM2-7 ring open 
during MCM loading (Frigola et al., 2017). In this model, Cdt1 must engage the MCM2-7 
complex at two distinct points to maintain the Mcm2/Mcm5 “gate” open for DNA entry during 
MCM loading.  
The existence of a second MCM2-7 binding site in the central region of Cdt1 sheds light 
on the mechanism of Cdt1 inhibition by the origin licensing inhibitor protein, Geminin. Previous 
studies have shown that Geminin inhibits Cdt1 by blocking its interaction with the MCM 
complex (Yanagi et al., 2002; Cook et al., 2004). The molecular mechanism of that interference 
cannot be easily explained if the only place MCM binds Cdt1 is the C-terminal domain. The co-
crystal structure of Cdt1 in complex with Geminin includes only the central region of Cdt1 
(including R210) and not the C-terminal domain (Lee et al., 2004). If the central domain is also 
essential for MCM2-7 binding, then we postulate that it is only this interaction that geminin 
targets. Moreover, poor binding at either interface is sufficient to impair overall MCM2-7 binding 
and therefore, MCM2-7 loading.  
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Dwarfism Hypermorphic Allele 
 
Cdt1 is tightly regulated throughout the cell cycle to ensure once-and-only once DNA 
replication. One of the mechanisms to restrict Cdt1 activity outside of G1 phase and avoid re-
replication is ubiquitin-mediated proteolysis. This process is carried out by two E3 ubiquitin 
ligases, CRL4Cdt2 and SCFSkp2 (Nishitani et al., 2006) (Figure 2.8C, top). CRL4Cdt2 relies on 
chromatin-bound PCNA to ubiquitylate its PIP-degron containing substrates (Arias and Walter, 
2006; Jin et al., 2006; Havens and Walter, 2011). On the other hand, ubiquitylation of Cdt1 by 
SCFSkp2 is dependent on Cyclin/CDK phosphorylation generating a phosphodegron which is 
recognized by the Skp2 adapter subunit (Li et al., 2003; Liu et al., 2004). Given the proximity of 
the A66T mutation to the Cyclin/CDK binding motif coupled with the defect in Cyclin A and 
Skp2 binding, we first reasoned the hyperactivity of this variant was due to increased protein 
stability. Cdt1-A66T is not more stable than WT Cdt1 however, so impaired degradation does 
not explain this variant’s phenotype.  
Our comparison of Cdt1-A66T, an engineered null for Cyclin/CDK binding (Cdt1-Cy), 
and a variant that can bind Cyclin but cannot generate a phosphodegron (Cdt1-2A) directly 
demonstrated that Cyclin A-dependent regulation of Cdt1 involves more than just degradation, 
because mutating the phosphodegron had less impact than mutating the Cyclin/CDK binding site 
(Figure 2.11). We thus postulate that Cyclin/CDK also inhibits Cdt1 by non-degradation 
mechanisms. Coulombe et al. described a negative-regulatory PEST domain (a.a. 74-108) in 
mammalian Cdt1 that contains multiple candidate CDK phosphorylation sites (Coulombe et al., 
2013). This domain functions independently of either Geminin or the E3 ubiquitin ligase system. 
Deleting the PEST domain induced DNA re-replication similar to Cdt1-A66T. Cyclin/CDK may 
phosphorylate any of the other CDK target residues – either in the PEST domain or elsewhere - 
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which could inhibit Cdt1 activity. A total of 20 candidate CDK phosphorylation sites have been 
detected in human Cdt1 by mass spectrometry, and only 7 of these have been functionally tested 
so far (Pozo and Cook, 2016). Given the apparent efficient interaction of Cdt1 with Cyclin 
A/CDK, it is also possible that Cyclin binding itself inhibits Cdt1 activity independently of 
phosphoregulation. We are actively pursuing a molecular explanation for non-degradative Cdt1 
inhibition by Cyclin A/CDK. Chapter 3 in this work focuses specifically on the 
phosphoregulation of Cdt1 and provides further mechanistic insights into this unexpected Cyclin 
A/CDK-dependent regulation of Cdt1. 
It is surprising that mutational alterations that lead to similar phenotypes in Meier-Gorlin 
Syndrome dwarfism patients behave differently at the molecular level with respect to Cdt1. In 
the case of Cdt1-R462Q and Cdt1-E468K, impaired Cdt1-MCM interactions can lead to G1 
phase lengthening and thus slower proliferation, because G1 length and origin licensing status 
are coordinated by an origin licensing checkpoint. Of note, the transformed U2OS cells used in 
this study have a less active licensing checkpoint relative to untransformed fibroblasts (Shreeram 
et al., 2002; Nevis et al., 2009). Thus, otherwise normal Meier-Gorlin patient cells may have 
experienced even longer G1 phases in vivo from a more robust checkpoint. Indeed, Meier-Gorlin 
Syndrome patient-derived cells proliferate slowly in culture (Bicknell et al., 2011b). Over the 
full course of development, the accumulated effects of slightly longer G1 phases could explain 
the overall short stature and hypoplasias associated with these hypomorphic alleles of cdt1 and 
likely other genes encoding licensing proteins. Perhaps the tissue-specific phenotypes reflect 
differences in the severity of the licensing defect in those cell types or alternatively, differences 
in the execution of the cellular response to impaired licensing. On the other hand, Cdt1-A66T 
dysregulation by Cyclin/CDK results in rereplication-induced stress, which can also lead to 
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proliferation failure, but in this case by checkpoint activation in S or G2 phase rather than G1. 
Even cells expressing endogenous levels of Cdt1-A66T in place of endogenous Cdt1 re-
replicated and spent more time in S and G2 phases due to the replication stress (Figure 2.5).  The 
ultimate outcome from either hypo- or hypermorphic mutations however is impaired overall 
proliferation (Figure 2.13). Continual improvements in our understanding of the molecular 
mechanisms governing origin licensing are essential to link processes of cell proliferation, 
genome stability, and development. 
Materials and Methods 
Cell culture and manipulations 
U2OS Flp-in Trex (Malecki et al., 2006) cells bearing a single FRT site (gift of J. Aster) 
and HEK 293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 1x penicillin/streptomycin (complete 
medium); cell line identity was verified by STR profiling, and the cells tested negative for 
mycoplasma. To generate stable isogenic cell lines, U2OS cells were co-transfected with flippase 
recombinase (Flp) and a Cdt1 expression vector derived from pcDNA5/FRT/TO-Venus-Flag-
Gateway (1124), a gift from Jonathon Pines (Addgene plasmid # 40999), using X-tremeGENE 
HP DNA transfection reagent (Roche). The Cdt1 cDNAs encode normal Cdt1 or harbor a single 
point mutation and a drug resistance cassette. 48 hrs post-transfection, cells were selected for 
resistance to either 150 µg/mL hygromycin B (Roche) or 1 µg/mL puromycin (Sigma) 
depending on the Cdt1 vector used. For inducible expression of Cdt1 variants, U2OS cells were 
treated with varying concentrations of doxycycline ranging from 0.003 µg/mL-1 µg/mL 
(CalBiochem) by either media exchange or adding directly into cell culture plates. For colony 
forming assays, U2OS cells harboring Cdt1 mutant alleles were plated at a density of ~500 cells/ 
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6 cm dish in the presence or absence of doxycycline. Cells were grown for 10 days, changing 
media every three days, and stained using 0.4% crystal violet (Fisher Scientific). Colony 
numbers and size were quantified using ImageJ (NIH). A technical replicate plate was harvested 
after 72 hours to assay for immunoblot analysis.  
For G1 to S phase synchronization, U2OS cells were treated with 2.5 mM thymidine for 
24 hours followed by release into complete medium containing 100 ng/mL nocodazole plus 0.05 
µg/mL doxycycline for 16 hours. Cells were then harvested by mitotic shake-off and re-plated in 
complete medium plus 0.05 µg/mL doxycycline for each time point. For S to G2/M phase 
synchronization, U2OS cells were treated with 2.5 mM thymidine for 18 hours followed by 
release into complete medium for 8 hours. Cells were then treated with 2.5 mM thymidine plus 
doxycycline for 18 hours followed by release into complete medium plus doxycycline for each 
time point. To transiently express Cdt1 variants, HEK 293T cells were transfected with Cdt1 
expression vectors using PEI Max (Sigma) according to the manufacturer’s instructions. HEK 
293T cells were harvested after 16 hours post-transfection and processed for subsequent co-
immunoprecipitation assays. 
All cell lines were validated by STR profiling and tested mycoplasma-negative. 
Plasmids  
Cdt1 mutations (Cdt1-A66T, -Q117H, -R210C, -R453W, -R462Q, -E468K) were 
generated by PCR-based mutagenesis from a WT Cdt1 coding sequence template. The resulting 
PCR products were cloned into pENTR vectors harboring the full-length Cdt1 sequence with C-
terminal polyhistidine (His) and hemagglutinin (HA) epitope tags. The Cdt1-Y520X truncation 
was generated using Gibson Assembly (NEB) from a pENTR plasmid harboring a WT version of 
Cdt1 with C-terminal polyhistidine and HA epitope tags, following the manufacturer’s protocols. 
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The pENTR-EGFP (vector control) plasmid was generated by subcloning EGFP from an EGFP 
bearing plasmid into pENTR via Gateway Cloning (Invitrogen). EGFP, Cdt1-WT-His-HA, Cdt1-
Y520X-His-HA, Cdt1-Mutant-His-HA, Cdt1-Cy-His-HA, and Cdt1-2A-His-HA versions were 
transferred from pENTR plasmids into derivatives of pcDNA5/FRT/TO-Venus-Flag-Gateway 
(1124), harboring either hygromycin B (Roche) or puromycin (Sigma) selection cassettes, via 
Gateway Cloning. The mVenus tagged constructs were constructed by subcloning mVenus into 
the Cdt1-WT-His-HA or the Cdt1-A66T-His-HA pENTR plasmids before Gateway cloning into 
pcDNA5/FRT/TO-Venus-Flag-Gateway (1124). 
Flow cytometry analysis for DNA re-replication  
U2OS cell lines harboring stably integrated individual Cdt1 alleles were cultured in 
complete medium plus doxycycline for either 48 or 72 hours. Cell were pulse labeled with 10 
µM EdU (Sigma) for 30 minutes prior to harvesting by trypsinization. Approximately 20% of 
this suspension was reserved for subsequent immunoblotting analysis. The remaining 80% was 
fixed in 1 x PBS plus 4% paraformaldehyde (Sigma) at room temperature for 15 minutes. Cells 
were permeabilized in 1% BSA plus 0.5% triton X-100 for 15 minutes then processed for EdU 
detection by conjugation to Alexa Fluor 647 azide (Life Technologies) in 1 mM CuSO4 and 100 
mM ascorbic acid; total DNA was detected by staining with 1 µg/mL DAPI (Life Technologies) 
in 100 µg/mL RNAse A (Sigma). Samples were analyzed on a Beckman Coulter CyAn ADP 
cytometer and data analyzed using FCS Express 6 (De Novo Software) software.  
MCM loading analysis by flow cytometry  
U2OS cells lines harboring stably integrated individual Cdt1 alleles were plated into 
dishes containing a mixture of siRNA (100 nM final concentration), Dharmafect 1 (Dharmacon), 
and antibiotic free media plus doxycycline for 72 hours. Cells were pulse labeled with 10 µM 
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EdU (Sigma) for 30 minutes prior to harvesting by trypsinization. Approximately 20% of this 
suspension was reserved for subsequent immunoblotting analysis while the remaining 80% was 
analyzed for bound MCM as described and validated in Matson et al. (Matson et al., 2017) and 
(Haland et al., 2015; Moreno et al., 2016). Briefly, cells were extracted in cold CSK buffer (10 
mM Pipes pH 7.0, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2) supplemented with 0.5% 
triton X-100, protease inhibitors (0.1 mM AEBSF, 1 µg/mL pepstatin A, 1 µg/mL leupeptin, 1 
µg/mL aprotinin), and phosphatase inhibitors (10 µg/mL phosvitin, 1 mM β-glycerol phosphate, 
1 mM Na-orthovanadate). Cells were washed with PBS plus 1% BSA and then fixed in 4% 
paraformaldehyde (Sigma) followed by processing for EdU conjugation to Alexa Fluor 647 azide 
(Life Technologies). Bound MCM was detected by incubation with anti-MCM2 primary 
antibody at 1:200 dilution and anti-mouse-488 at 1:1,000 dilution at 37 °C for 1 hour. Total 
DNA was detected by incubation in 1 µg/mL DAPI (Life Technologies) and 100 µg/mL RNAse 
A (Sigma). Samples were processed on a Beckman Coulter CyAn ADP cytometer and data 
analyzed using FCS Express 6 (De Novo Software) software. Control samples were prepared 
omitting primary antibody or EdU detection to define thresholds of detection as in Matson et al 
2017. 
Antibodies 
The following antibodies were purchased from Cell Signaling Technologies: anti-pChk1 
S345 (Cat# 2341), anti-Chk1 (Cat# 2345), anti-Cdt1 (Cat# 8064), anti-Skp2 (Cat# 4313). Anti-
HA used for immunoblotting was purchased from Roche (Cat# 11867423001). Anti-HA used for 
co-immunoprecipitation was purchased from Santa Cruz Biotechnology (Cat# SC-805). Anti-
Cyclin A was purchased from Santa Cruz Biotechnology (Cat# SC-596). Anti-MCM2 was 
purchased from BD Biosciences (San Jose, CA, Cat#610700). Anti-mouse Alexa 488 (Jackson 
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ImmunoResearch) and Alexa 647-azide (Life Technologies) were used in flow cytometry 
analyses. Secondary antibodies for immunoblotting were purchased from Jackson 
ImmunoResearch. 
Protein-protein interaction assays 
 
For HEK 293T co-immunoprecipitation assays, cells were transiently transfected using 
expression vectors harboring individual Cdt1 alleles. Cells were harvested by trypsinization, 
pelleted, and resuspended in co-IP Buffer (50 mM HEPES pH 7.2, 33 mM KAc, 1 mM MgCl2, 
0.5% triton X-100, 10% glycerol) containing protease inhibitors (0.1 mM AEBSF, 10 µg/mL 
pepstatin A, 10 µg/mL leupeptin, 10 µg/mL aprotinin), phosphatase inhibitors (5 µg/mL 
phosvitin, 1 mM β-glycerol phosphate, 1 mM Na-orthovanadate), 1 mM ATP, and supplemented 
with 5 mM CaCl2 and 15 units of S7 micrococcal nuclease (Roche). Lysates were sonicated for 
10 seconds on low power followed by incubation on ice for 20 minutes and clarification by 
centrifugation at 13,000 x g at 4°C. Supernatants were pre-cleared with Protein A-Agarose 
(Roche) then incubated with 1 µg antibody at 4°C overnight with rotation. Antibody-antigen 
complexes were collected on Protein A beads at 4°C for 1 hour with rotation. Complexes were 
washed 3 times rapidly with 1 mL ice-cold co-IP buffer then eluted by boiling in SDS sample 
buffer supplemented with 10% β-ME and 100 mM DTT for subsequent immunoblot analysis.  
For polyhistidine pulldown assays, U2OS cells harboring each individual allele were 
plated in complete medium plus 1 µg/mL doxycycline for 16 hours, then lysed in 50 mM HEPES 
pH 8.0, 33 mM KAc, 117 mM NaCl, 20 mM Imidazole, 0.5% triton X-100, 10% glycerol) 
containing protease inhibitors (0.1 mM AEBSF, 10 µg/mL pepstatin A, 10 µg/mL leupeptin, 10 
µg/mL aprotinin), phosphatase inhibitors (5 µg/mL phosvitin, 1 mM β-glycerol phosphate, 1 mM 
Na-orthovanadate), 1 mM ATP, 1 mM MgCl2, and supplemented with 5 mM CaCl2 and 15 units 
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of S7 micrococcal nuclease (Roche). Clarified lysates were incubated with nickel NTA agarose 
(Qiagen) for 2 hours at 4°C with rotation. Beads were washed 4 times rapidly with 1 mL ice cold 
lysis buffer then boiled in sample buffer prior to immunoblot analysis. 
Live-cell imaging and analysis 
U2OS cells stably expressing a PCNA-mTurquoise2 fusion (introduced by retroviral 
transduction) were plated on glass-bottom plates (Cellvis) #1.5 in FluoroBrite DMEM 
(Invitrogen) supplemented with FBS, L-glutamine, and penicillin/streptomycin and kept in a 
humidified chamber (Okolabs) at 37°C with 5% CO2. A Nikon Ti Eclipse inverted microscope 
with Plan Apochromat dry objective lenses 20x (NA 0.75), Nikon Perfect Focus System and 
Andor Zyla 4.2 sCMOS detector with 12 bit resolution was used for imaging. For fluorescence 
imaging Chroma filters were optimized for YFP spectral range - excitation: 500/20 nm, beam 
splitter: 515 nm and emission: 535/30 nm. Images were collected every 10 minutes using NIS-
Elements AR software. No photobleaching or phototoxicity was observed in imaged cells. 
Expression of Cdt1 (WT/A66T) – mVenus was induced with 50 ng/ml Dox (A66T) or 100 ng/ml 
Dox (WT).  
Image and data analysis were performed using Fiji, ImageJ NIH (Schindelin et al., 2012) 
software (version 1.51n) and Matlab (R2017b MathWorks). Briefly, asynchronous colonies of 
cells were followed in time-lapse experiments and individual cells were tracked, segmented and 
synchronized in silico. Before the analysis, images were background corrected using rolling ball 
subtraction. Individual cells were tracked in a user-assisted way and nuclear regions were 
segmented based on PCNA images. These regions of interest were used to measure Cdt1 
(WT/A66T) – mVenus intensity. Cells in S phase were detected based on S-phase punctate 
pattern of PCNA by calculating the variance of fluorescence intensity of PCNA in a spatial scale 
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corresponding to foci size. Cells lacking sufficient PCNA contrast to confidently detect S phase 
boundaries were manually removed from the analysis set. To visualize dynamics of mean Cdt1 
(WT/A66T) signal throughout the cell cycle in a population of cells, the signals collected from 
individual cells were normalized to cell cycle type in this manner: cell cycle phases were defined 
for individual cells based on PCNA localization, and traces of Cdt1 intensity were linearly 
interpolated over the expected number of time points in each cell cycle phase (based on 
measurements of median cell cycle phase lengths in the population). This in silico alignment 
emphasized the sharp changes in protein abundance at the boundaries of cell cycle phases rather 
than the smoothing from averaging cells with different lengths of individual phases. 
Structural model of hMCM complex with hCdt1 middle domain and C-terminal winged-helix 
domain 
The atomic resolution structure of the yeast MCM2-7, Cdc6, ORC1-6, and Cdt1 complex 
was determined by electron microscopy at a resolution of 3.9 Å (PDB ID 5udb (Yuan et al., 
2017)). This structure was the template used for modeling the atomic structures of the human 
MCM (hMCM) complex as well as the interaction of human Cdt1 (hCdt1) with hMCM. MCM 
subunits are highly conserved during evolution, with yeast and human subunits sharing 46-50% 
sequence identity. Human and yeast MCM2, MCM4 and MCM6 subunits, in particular, share 
50%, 47% and 47% sequence identity, respectively. Modeller v9.16 (Marti-Renom et al., 2000) 
was used to generate the structural models of human MCM subunits using the yeast MCM 
subunits (PDB ID 5udb) as a template. No modeling of hCdt1 was needed as X-ray 
crystallography had been used to determine the structure of the N-terminal winged helix domain 
of hCdt1 at a resolution of 3.3 Å (PDB ID 2wvr (De Marco et al., 2009)), while the C-terminal 
winged helix domain of mouse Cdt1 was determined at 1.89 Å resolution (PDB ID 3a4c 
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(Khayrutdinov et al., 2009)). Due to the low sequence conversation between yeast and human 
Cdt1, the two mammalian winged helix domains were superimposed on the corresponding yeast 
Cdt1 winged helix domains in 5udb using the sequence-independent and structure-based 
dynamic programming alignment method accessed through the ‘align’ command in the PyMOL 
molecular vision system (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, 
LLC.). 
Quantification and statistical analyses 
Data were analyzed using GraphPad Prism 7.0 and MATLAB and Statistics Toolbox 
Release  
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CHAPTER 3: PHOSPHOREGULATION OF CDT1 IN G2 AND M PHASES PREVENTS 
RE-REPLICATION INDEPENDENTLY OF GEMININ3 
 
Project Summary 
This chapter represents a currently ongoing project where I made significant 
contributions to the derivation of cell lines and methods optimization. The first author in this 
study, Yizhuo Zhou (a former postdoc in our lab) wrote the majority of this section with help 
from our mentor, Dr. Jean Cook, and input from co-authors. As a co-author in the study I made 
initial in vitro observations showing inhibition of Cdt1-MCM interactions using a GST-tagged 
Cdt1 phosphomimetic variant. This initial result, together with results reported in Chapter 2, 
contributed to the discovery of an unexpected mechanism of Cdt1 phosphoregulation by Cyclin 
A/Cdk1 to prevent re-replication. Zhuo et al. also showed that the inhibition of re-replication 
happens independently of Geminin in G2 and M phases. Furthermore, Zhuo et al. addressed the 
need to re-activate Cdt1 in G1 for origin licensing and showed that PP1 is the phosphatase 
responsible for Cdt1 dephosphorylation and thus re-activation. Together, these results suggest 
that distinct, non-redundant re-replication inhibition mechanisms act in a sequential relay from 
early S phase through mitosis to ensure once, and only once, chromosome duplication. Since the 
                                                          
3Modified from: Zhou, Y., Stone, H.M., Oh, S., Pozo, P.N. and Cook, J.G. Phosphoregulation of 
Cdt1 in G1 and M phases prevents re-replication independently of Geminin. bioRxiv. 366666; doi: 
https://doi.org/10.1101/366666. Zhou, Y. generated all of the data unless otherwise noted in the 
figure legends. 
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departure of Yizhuo from the lab, I took over the final stages of the project and will bring it to 
completion.  
Introduction 
Accurate DNA replication in S phase must be completed precisely once per cell cycle. A 
prerequisite for DNA replication in eukaryotic cells is the DNA loading of the central core of the 
replicative helicase, the minichromosome maintenance complex (MCM). The process of MCM 
loading is called DNA replication origin licensing, and it should be tightly restricted to the G1 
cell cycle phase (Masai et al., 2010; Siddiqui et al., 2013). In proliferating mammalian cells, 
many hundreds of thousands of replication origins are licensed in G1, then a subset of these 
origins initiate replication in S phase, but no origin should initiate more than once per cell cycle 
(Arias and Walter, 2007; Li and Jin, 2010; Mechali, 2010; Truong and Wu, 2011). Improper re-
licensing in S, G2, or M phases can lead to re-initiation and re-replication, a source of DNA 
damage and genome instability that can promote cell death or oncogenesis (Hook et al., 2007; 
Blow and Gillespie, 2008). For example, de-regulated licensing factors in adult mice caused 
replication stress, DNA re-replication, and oncogenesis (Shima et al., 2007; Bua et al., 2015; 
Munoz et al., 2017). Licensing factors are also deregulated in a wide variety of spontaneous 
human cancers (Liontos et al., 2007; Petropoulou et al., 2008; Mahadevappa et al., 2017). 
Re-replication is normally avoided by inhibiting essential MCM loading proteins 
throughout S, G2, and M phase. These essential proteins include the origin recognition complex 
(ORC), a direct origin DNA binding complex, which recruits and cooperates with the Cdc6 (cell 
division cycle 6) protein. ORC and Cdc6 then recruit Cdt1 (Cdc10-dependent transcript 1) bound 
to the MCM complex, and altogether these factors load MCM onto DNA during G1. Each of the 
loading factors is tightly regulated through combinations of transcription, protein 
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phosphorylation, and ubiquitin-mediated degradation to restrict licensing activity to G1 phase 
(Nguyen et al., 2001; Bell and Dutta, 2002; Pozo and Cook, 2016). Although many mechanisms 
to avoid re-licensing and re-replication have been described, we postulate that the set of known 
mechanisms is not comprehensive enough to fully explain how hundreds of thousands of 
mammalian origins are tightly controlled, nor how re-replication control mechanisms might vary 
in different cell cycle phases. 
One of the known mechanisms to avoid re-replication is degradation of mammalian Cdt1 
in S phase. Beginning in late S phase however, Cdt1 re-accumulates and reaches levels in G2 
phase similar to its levels in G1 (Pozo and Cook, 2016),(Nishitani et al., 2001; Chandrasekaran et 
al., 2011). Cdt1 licensing activity is blocked in late S, G2, and M phases by binding to a 
dedicated inhibitor protein, Geminin, which interferes with Cdt1-MCM binding (Wohlschlegel et 
al., 2000; Klotz-Noack et al., 2012; Pozo and Cook, 2016). Cdt1 is also hyperphosphorylated in 
G2 phase(Nishitani et al., 2001; Chandrasekaran et al., 2011), but the molecular and 
physiological consequences of those modifications are largely unknown. In general, mechanisms 
of Cdt1 activity control are poorly understood because the role of Cdt1 in licensing itself is also 
incompletely understood. Unlike the other licensing proteins that are AAA+ ATPases (Borlado 
and Mendez, 2008; Li and Stillman, 2012; Bell and Botchan, 2013), Cdt1 is not an enzyme. 
Moreover, Cdt1 is not as highly conserved among eukaryotic species as ORC, Cdc6, and MCM 
are, and there is no full-length structure of any metazoan Cdt1 (Pozo and Cook, 2016). 
Determining mechanisms of Cdt1 activity control can shed light on Cdt1 function. Here, we 
elucidated a novel phosphorylation-dependent mechanism of Cdt1 inhibition that complements 
other re-replication control mechanisms to ensure precise genome duplication. 
76 
 
 We analyzed the re-replication consequences of mutationally altered Cdt1 variants that 
cannot be hyperphosphorylated in G2. We discovered that Cdt1 phosphorylation in a disordered 
linker region previously implicated in stress-induced licensing inhibition prevents re-replication 
in human cells. We demonstrated that Cyclin A/CDK1 is the major Cdt1 kinase in G2 and M 
phases, and defined a phosphorylation-mediated mechanism to block Cdt1-MCM binding that is 
independent of contributions from Geminin. This inhibition then creates a requirement for PP1-
dependent Cdt1 dephosphorylation to reactivate licensing in the subsequent G1. We propose that 
multiple re-licensing inhibition mechanisms are not simply redundant, but rather act in a 
sequential relay from early S phase (replication-coupled destruction) through mid-S phase 
(degradation plus Geminin) to G2 and M phase (Geminin plus Cdt1 hyperphosphorylation) to 
achieve stringent re-replication control for large metazoan genomes. 
Results  
Cdt1 phosphorylation inhibits DNA re-replication 
Human Cdt1 is phosphorylated in G2 phase and mitosis, and we hypothesized that this 
phosphorylation inhibits re-replication by directly inhibiting Cdt1 activity. To test that 
hypothesis, we compared the activity of normal Cdt1 (wild-type, WT) or an unphosphorylatable 
Cdt1 variant, “Cdt1-5A”. We had previously shown that this variant, “Cdt1-5A” (S391A, 
T402A, T406A, S411A, and S491A) is both virtually unphosphorylatable in vitro by stress-
induced MAP kinases, and is compromised for G2 hyperphosphorylation detected by gel 
mobility shift (Chandrasekaran et al., 2011). Cdt1-5A bears alanine substitutions at five sites, 
and four are in a region of low sequence conservation and high-predicted intrinsic disorder 
(Figure 3.1a and Figure 3.2). This “linker” region connects the two domains of Cdt1 that have 
been structurally characterized for Geminin binding (a middle “M domain”) and for MCM  
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Figure 3.1. 
 
Figure 3.1. Unphosphorylatable Cdt1 induces re-replication and DNA damage.  
(a) Schematic of the human CDT1 protein. CDT1 contains two structurally-characterized 
domains, the Geminin and MCM binding domain (M) and a C-terminal MCM binding domain 
(C). The Ser/Thr-Pro sites that were altered for this study are marked with green ovals, and the 
cyclin binding motif is marked with a green triangle. Positions are T29, S31, S372, S391, S394, 
T402, T406, S411, and S491; the cyclin binding motif (Cy) is 68-70. Human CDT1 was aligned 
with 26 other vertebrate Cdt1 sequences using ClustalW, and a relative conservation score was 
derived (see also Methods and Figure 3.2). The blue heatmap indicates relative conservation at 
each amino acid position of human Cdt1. An intrinsic disorder score was also derived for human 
Cdt1 and shown as the corresponding orange heatmap. (b) Asynchronously-growing U2OS cells 
with integrated inducible Cdt1 constructs or the parent line (control) were cultured in 1 μg/ml 
doxycycline for 48 hours. Whole cell lysates were subjected to immunoblotting for ectopic (HA) 
or endogenous and ectopic Cdt1; Ponceau S staining of the blot serves as a loading control. (c) 
Asynchronously-growing U2OS cells were treated with 1 µg/mL doxycycline for 48 hours and 
labeled with EdU for 1 hour before harvesting. Cells were analyzed by flow cytometry for DNA 
content with DAPI and for DNA synthesis by EdU detection; the gating scheme is illustrated. 
One representative of more than four independent biological replicates is shown. The bar graph 
plots the percentages of re-replicating cells across all experiments. Asterisks indicate statistical 
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significance (*** p<0.001) determined by Mann–Whitney U-test. n.s. = not significant. Error 
bars indicate standard deviation. (d) Asynchronously-growing U2OS cells were treated with 1 
µg/mL doxycycline for 48 hours, and whole cell lysates were probed for phospho-Chk1 (S345), 
total Chk1, HA-Cdt1, and total protein (Ponceau S); at least two independent experiments were 
probed and one example is shown. (e) The same cell lines in (b) were synchronized in 
prometaphase (“G2/M”) by sequential thymidine and nocodazole treatment. Whole cell lysates 
were separated by standard SDS-PAGE (top) or Phos-tag SDS-PAGE followed by 
immunoblotting for ectopic Cdt1 (HA); Ponceau S staining serves as a loading control. 
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Figure 3.2. 
 
Figure 3.2. Cdt1 phosphorylation sites in 27 vertebrate sequences.  
A representative selection of 28 vertebrate sequences for comparison was taken from Miller et 
al.(Miller et al., 2007) and Cdt1 protein sequences retrieved from https://www.uniprot.org/. For 
the alignment, Xenopus tropicalis Cdt1 was replaced with Xenopus laevis Cdt1, Tupaia 
belangeri was replaced with Tupaia chinensis, and no Cdt1 sequence for Echinops telfairi 
(tenrec) was available. These 27 full-length sequences were aligned with ClustalW at 
https://www.genome.jp/tools-bin/clustalw using the default settings, and the resulting alignment 
was visualized with BoxShade, 50% identity or similarity were shaded medium and light grey 
(https://embnet.vital-it.ch/software/BOX_form.html ). The portion corresponding to the Cdt1 
linker domain is shown using common names. All potential CDK/MAPK phosphorylation sites 
are shaded green, and an 85 residue insertion in chicken Cdt1 (lacking any potential 
CDK/MAPK phosphorylation sites) was deleted for clarity. The 27 sequences are from the 
following species: Homo sapiens, Pan troglodytes, Macaca mulatta, Otolemur garnettii, Tupaia 
chinensis, Rattus norvegicus, Mus musculus, Cavia porcellus, Oryctolagus cuniculus, Sorex 
araneus, Erinaceus europaeus, Canis familiaris, Felis catus, Equus caballus, Bos Taurus, 
Dasypus novemcinctus, Loxodonta Africana, Monodelphis domestica, Ornithorhynchus anatinus, 
Gallus, Anolis carolinensis, Xenopus laevis, Tetraodon nigroviridis, Takifugu rubripes, 
Gasterosteus aculeatus, Oryzias latipes, and Danio rerio. 
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binding (C-terminal “C domain”)(Lee et al., 2004; Khayrutdinov et al., 2009). Because both 
cyclin dependent kinases (CDK) and MAP kinases share similar substrate sequence requirements 
(serine/threonine-proline), and because both are active in G2, we postulated that during normal 
G2 and M phases these Cdt1 sites are phosphorylated by CDK or MAPK (Hall and Vulliet, 
1991). We inserted cDNAs encoding either wild-type Cdt1 (Cdt1-WT) or Cdt1-5A into a single 
chromosomal FRT recombination site under doxycycline-inducible expression control in U2OS 
osteosarcoma cells. Both Cdt1 constructs bear C-terminal HA epitope and polyhistidine tags to 
distinguish ectopic Cdt1 from endogenous Cdt1.  
As a measure of relative Cdt1 activity, we induced Cdt1 overproduction to approximately 
5-10 times more than endogenous Cdt1 (Figure 3.1b, compare lanes 1 and 2). The amount of 
re-replication induced by Cdt1 overproduction is directly related to Cdt1 licensing activity (Teer 
and Dutta, 2008). As previously reported (Vaziri et al., 2003; Nishitani et al., 2006), Cdt1-WT 
overproduction in human cells induced re-replication, which we detected by analytical flow 
cytometry as a population of cells with DNA content greater than the normal G2 amount (>4C, 
Figure 3.1c, and Figure 3.3b). Strikingly however, overproducing Cdt1-5A to the same level as 
Cdt1-WT induced substantially more re-replication suggesting that it is intrinsically more active. 
DNA re-replication can also induce the formation of giant nuclei (Melixetian et al., 2004; Zhu et 
al., 2004), and we noted that the average nuclear area of cells overproducing Cdt1-WT was 
somewhat larger than control nuclei, whereas nuclei of cells overproducing Cdt1-5A were even 
larger (Figure 3.4a). Thus, Cdt1-5A expression not only induces more cells to re-replicate, but it 
also induces a higher degree of re-replication in those cells than Cdt1-WT. 
Re-replication is an aberrant genotoxic phenomenon characterized by molecular markers 
of DNA damage (Zhao and Piwnica-Worms, 2001; Lin and Dutta, 2007; Truong and Wu, 2011).  
81 
 
Figure 3.3. 
 
Figure 3.3. Cdt1 is phosphorylated to inhibit DNA re-replication.  
(a) U2OS cells ectopically expressing HA-tagged Cdt1-WT were arrested with nocodazole and 
treated with 20 μM MG132 to prevent premature anaphase. Alternatively, cells were released for 
3 hours to obtain G1 cells. The cells were mock treated (lanes 3 and 4) or treated with 10 µM 
RO3306 (CDK1i, lane 5). Cell lysates were also mock treated (lane 3) or with lambda and CIP 
phosphatase (lane 4) for 30 minutes. The samples were then subjected to Phos-tag SDS-PAGE 
followed by immunoblotting with HA antibody. (b) Quantification of the experiments in (Figure 
3.1c) showing all cell cycle phase distributions (G1, S, G2/M, and re-replication). n >4.  
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Figure 3.4. 
 
Figure 3.4. Unphosphorylatable Cdt1 induces giant nuclei formation and DNA damage.  
(a) U2OS cells were treated with 1 µg/mL doxycycline for 48 hours before fixation and staining 
with DAPI. Nuclear sizes were analyzed by measuring DAPI area using Photoshop software. 
The average nuclear area of cells overproducing Cdt1-WT was 1.2 fold larger than control cells, 
whereas cells expressing Cdt1-5A had even larger average nuclear area (~1.7 fold higher than 
control cells). Representative results of two independent experiments are shown; total numbers 
of cells analyzed is listed under the histograms. Asterisks indicate statistical significance (*** 
p<0.001, ** p<0.01) determined by Mann–Whitney U -test. Mean +/- standard deviation is 
indicated. (b) U2OS cells were treated as indicated in (a) and stained with an anti-γH2AX 
antibody (green). Nuclei were stained with DAPI (blue). Representative results of two 
independent experiments are shown. Quantification of the percentage of γH2AX positive cells is 
shown with the total number of cells analyzed listed under the histogram. 
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As an independent measure of re-replication, we analyzed lysates of Cdt1-overproducing cells 
for Chk1 phosphorylation, a marker of the cellular DNA damage response. Cdt1-5A consistently 
induced more Chk1 phosphorylation than WT Cdt1 (Figure 3.1d, compare lanes 2 and 3). We 
also noted that the accumulation of re-replicated cells came at the expense of G1 cells, consistent 
with a checkpoint arrest (Figure 3.3b). Moreover, cells overproducing Cdt1-5A were also ~3 
times more likely to generate γ-H2AX foci, another marker of re-replication-associated DNA 
damage (Rakotomalala et al., 2008; Klotz-Noack et al., 2012) (Figure 3.4b). We thus conclude 
that phosphorylation at these sites negatively regulates Cdt1 activity. 
In nocodazole-arrested (early mitotic) cells, phosphorylated Cdt1-WT migrated more 
slowly by SDS-PAGE than Cdt1-5A (Figure 3.1e, lanes 2 and 5). As a better measure of Cdt1 
phosphorylation, we analyzed Cdt1 gel migration in the presence of Phos-tag reagent which 
retards protein mobility proportional to the extent of phosphorylation (Kinoshita et al., 2009). 
Endogenous Cdt1 from nocodazole-arrested cells migrates much more slowly on Phos-tag gels 
than endogenous Cdt1 from G1 cells, and this slow migration was reversed by phosphatase 
treatment (Figure 3.3a). We detected similar slow Cdt1 migration in G2 cells synchronized by 
release from a thymidine arrest without the nocodazole block (data not shown), so we presume 
that the phosphorylation in prometaphase reflects phosphorylation from late S phase through 
mid-mitosis (i.e. “G2/M”). The distribution of ectopic Cdt1-5A bands was lower than Cdt1-WT 
bands on Phos-tag gels, demonstrating that these sites are indeed phosphorylated late in the cell 
cycle. 
Phosphorylation at two additional candidate CDK/MAPK target sites in the linker region 
has been reported from global phosphoproteomics studies(Hornbeck et al., 2015). To test the 
potential additional contribution of these sites to Cdt1 regulation, we included the mutations 
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S372A and S394A to Cdt1-5A to create Cdt1-7A (Figure 3.1a). This variant had slightly 
increased mobility on Phos-tag gels relative to Cdt1-5A (Figure 3.1e, compare lanes 5 and 6). 
On the other hand, Cdt1-7A overproduction did not consistently induce more re-replication or 
DNA damage than Cdt1-5A (Figure 3.1c, bar graph and Figure 3.1d, lanes 3 and 4). From 
this observation, we infer that Cdt1-5A is already at the lowest activity that can be achieved from 
phosphorylation in the linker region, and that additional phosphorylations do not cause further 
activity decreases. 
To assess the importance of the four sites in the linker relative to the single site in the C 
domain, we generated Cdt1-4A and Cdt1-S491A (Figure 3.1a). Cdt1-4A migrated on Phos-tag 
gels with a pattern very similar to Cdt1-5A whereas Cdt1-S491A migration was 
undistinguishable from Cdt1-WT (Figure 3.1e, lanes 2-5). Furthermore, Cdt1-4A was as active 
as Cdt1-5A for inducing re-replication, whereas Cdt1-S491A only induced as much re-
replication as Cdt1-WT (Figure 3.1c). Like Cdt1-5A, Cdt1-4A induced substantially more DNA 
damage (phospho-Chk1) than Cdt1-WT (Figure 3.1d, lanes 7-9). Thus, linker region 
phosphorylation is responsible for Cdt1 inactivation during G2 and M phases.  
Cdt1 is also known to be phosphorylated at both T29 and S31 (Miotto and Struhl, 2011; 
Hornbeck et al., 2015). Phosphorylation at T29 generates a binding site for the SCFSkp2 E3 
ubiquitin ligase, which contributes to Cdt1 degradation during S phase (Sugimoto et al., 2004; 
Takeda et al., 2005). Robust Cdt1 degradation in S phase is important for avoiding re-replication 
(Arias and Walter, 2005; Jin et al., 2006; Nishitani et al., 2006). The stress MAPK JNK (c-Jun 
N-terminal kinase) has also been reported to inhibit Cdt1 by phosphorylating T29 (Miotto and 
Struhl, 2011). To determine if these N-terminal phosphorylations add to the effects of linker 
region phosphorylations, we added the two mutations, T29A and S31A, to Cdt1-7A to generate 
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Cdt1-9A. Cdt1-9A from nocodazole-arrested cells migrated even faster than Cdt1-7A on Phos-
tag gels (similar to phosphatase-treated WT Cdt1, not shown), demonstrating that one or both 
T29 and S31 are phosphorylated after S phase, although Cdt1 is not as unstable in G2 as it is in S 
phase. Cdt1-9A overproduction induced even more re-replication than Cdt1 bearing only linker 
region mutations, Cdt1-4A, 5A, and 7A (Figure 3.1c), and similar amounts of DNA damage 
checkpoint activation (pChk1, Figure 3.1d, lanes 5 and 9). We presume that compromised S 
phase degradation from loss of SCFSkp2 targeting contributes to this enhanced re-replication (Liu 
et al., 2004; Takeda et al., 2005; Nishitani et al., 2006).  
Cyclin A/CDK1 is the primary Cdt1 kinase during G2 and M phases 
To determine which kinase(s) is responsible for Cdt1 inactivation, we assessed the effects 
of kinase inhibitors. All nine of the sites in Cdt1-9A can be targeted by both CDKs and MAPKs 
since all nine are serine or threonine followed by proline (Figure 3.2). We synchronized cells in 
nocodazole when Cdt1 is maximally phosphorylated and then tested the effects of 
pharmacological MAPK and CDK inhibitors on the migration of endogenous Cdt1 by Phos-tag 
gel analysis. We first treated nocodazole-arrested cells with pharmacological inhibitors of p38 or 
JNK, two stress-activated MAP kinases which we previously showed can phosphorylate the 
linker region and inactivate origin licensing during a stress response (Chandrasekaran et al., 
2011) (p38 inhibitor SB203580 and c-Jun N-terminal kinase JNK inhibitor VIII). These MAPK 
inhibitors, either alone or in combination, had no effect on mitotic Cdt1 migration on Phos-tag 
gels (Figure 3.5a, lanes 8-10, compared to lane 4). We confirmed that the inhibitors were 
active in these cells at these concentrations by analyzing known downstream substrates (Figure 
3.6a-c)(Mailand and Diffley, 2005; Wu et al., 2010; Chandrasekaran et al., 2011; Sakurikar et 
al., 2012; Tollenaere et al., 2015). We also tested inhibitors of CDK1 and CDK2 singly or in  
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Figure 3.5. 
 
Figure 3.5. Cdt1 hyper-phosphorylation requires Cyclin A/CDK1.  
(a) U2OS cells were synchronized with nocodazole then mock treated or treated with 10 µM 
RO3306 (lane 5), 6 µM CVT313 (lane 6), 30 µM SB203580 (lane 8), 10 µM JNK inhibitor VIII 
(lane 9), or combinations of inhibitors (lane 7,10,11) as indicated for 1 hour except the RO3306 
was treated for only the final 15 minutes. All cells were simultaneously treated with 20 μM 
MG132 to prevent premature mitotic exit. Alternatively, cells were released for 3 hours to obtain 
G1 cells or subjected to 20 J/m2 to induce Cdt1 degradation. Endogenous Cdt1 phosphorylation 
was assessed by standard or Phos-tag SDS-PAGE followed by immunoblotting; Ponceau S 
staining serves as a loading control. The example shown is representative of more than three 
independent experiments. (b) HEK 293T cells expressing GFP, His-tagged Cdt1-WT or a Cdt1-
variant that cannot bind CDKs (Cdt1-Cy) were synchronized with nocodazole and harvested by 
mitotic shake off. Cdt1 was retrieved on nickel-agarose, then both the whole cell lysates (lanes 1-
3) and bound fractions (lanes 4-6) were probed for the indicated proteins by immunoblotting. 
The result is representative of at least two independent experiments. 
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Figure 3.6. 
 
Figure 3.6. Validation of inhibitor activities.  
(a) U2OS cells were treated as indicated in Figure 3.7a. Mitotic phosphoproteins were analyzed 
by immunoblotting with an anti-Mpm-2 antibody. Mitotic phosphoprotein mAb2 (MPM-2) is a 
mitotic marker that recognizes a large subset of mitotic phosphoproteins and reflects CDK1 
activity in M phase(Wu et al., 2010). (b) U2OS cells were mock treated (lane 1) or treated with 6 
µM CVT313 (lane 2), then probed for endogenous Cdc6. Cdc6 is stabilized by CDK2/Cyclin E 
activity during late G1 phase(Mailand and Diffley, 2005). (c) U2OS cells were mock treated 
(lane 2), treated with UV light (lane 1), or arrested in G2/M phase (lane 3) followed by 30 µM 
SB203580 treatment (lane 4). The mitogen-activated protein kinase-activated protein kinase 2 
(MK2) is a direct substrate of p38(Tollenaere et al., 2015). The phosphorylation and total protein 
levels of MK2 were analyzed by immunoblotting. Equal loading was confirmed by Ponceau S 
staining in all experiments, and representative results of two independent experiments are shown. 
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combination. The slow migration of phospho-Cdt1 was largely reversed by treatment with CDK1 
inhibitor RO3306 for just 15 minutes (Figure 3.5a, compare lanes 5, 7, and 11 to lane 4), but 
not when treated with the CDK2 inhibitor CVT313, (Figure 3.5a, lane 6). This effect occurred 
even in the presence of the proteasome inhibitor MG132, which we included in all kinase 
inhibitor experiments to prevent premature anaphase onset. 
CDK1 is normally activated by either Cyclin A or Cyclin B, and we sought to determine 
which cyclin is responsible for directing CDK1 to phosphorylate Cdt1. We therefore took 
advantage of the polyhistidine tag at the C-terminus of the Cdt1-WT construct to retrieve Cdt1 
from lysates of transiently transfected, nocodazole-arrested 293T cells. As a control, we included 
a Cdt1 variant with a previously-characterized mutation in the cyclin binding motif, Cdt1-Cy 
(Takeda et al., 2005) (RRL to AAA at positions 66-68, Figure 3.1a). We analyzed His-Cdt1-
bound proteins from these lysates for the presence of endogenous cyclin and CDK subunits. 
Cdt1-WT interacted with both CDK1 and CDK2, and strongly interacted with Cyclin A, but not 
at all with either Cyclin B or Cyclin E (Figure 3.5b). Cdt1-Cy retrieved no cyclins or CDKs, 
indicating that the only CDK binding site in Cdt1 is the RRL at positions 66-68. Since Cdt1 
binds Cyclin A, CDK1 and CDK2, but only inhibition of CDK1 activity affected Cdt1 
phosphorylation, we conclude that Cyclin A/CDK1 is responsible for the inactivating Cdt1 
phosphorylations during G2 and M phases.  
Cdt1 phosphorylation blocks MCM binding 
We next sought to determine by what mechanism Cyclin A/CDK1-mediated 
phosphorylation inhibits Cdt1 licensing activity. The inhibitory phosphorylation sites are in the 
linker region between the middle and C-terminal domains (Figure 3.1a), and these positions are 
not visible in any currently available Cdt1 atomic structures. Nonetheless, our recently-generated 
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homology model of the human Cdt1-MCM complex (Pozo et al., 2018) led us to speculate that 
phosphorylation-induced changes at this linker could inhibit MCM binding, either because the 
linker contacts MCM directly or because phosphorylation alters Cdt1 conformation or relative 
positions of the two MCM binding domains (Figure 3.7a). We thus set out to test if MCM 
interacts with hypophosphorylated G1 Cdt1 more effectively than with hyperphosphorylated G2 
Cdt1 (i.e. if phosphorylation impairs Cdt1-MCM binding). We noted however that simply 
comparing co-immunoprecipitations from lysates of G1 and G2 phase cells is complicated by the 
presence of the Cdt1 inhibitor, Geminin, which interferes with the Cdt1-MCM interaction 
(Yanagi et al., 2002; Cook et al., 2004) and is only present in the G2 cells. Because Geminin is 
differentially expressed in G1 and G2 cells, the comparison would not be fair. To account for the 
effects of Geminin, we prepared a lysate of asynchronously-proliferating cells which contain 
mostly G1 hypophosphorylated Cdt1; Cdt1 is degraded in S phase, and cells spend a relatively 
small fraction of total cell cycle time in G2 (e.g. Figure 3.3b). We mixed this lysate with lysate 
from nocodazole-arrested cells that contains both Geminin and hyperphosphorylated Cdt1. In 
this way, we created a similar opportunity for MCM to bind either hyper- or hypo-
phosphorylated Cdt1. We then immunoprecipitated endogenous MCM2 and probed for MCM6 
as a marker of the MCM complex and for tagged Cdt1. As a control, we immunoprecipitated 
MCM2 from an unmixed lysate of nocodazole-arrested cells. As expected, Geminin did not co-
precipitate with MCM since the Cdt1-Geminin and Cdt1-MCM interactions are mutually 
exclusive (Yanagi et al., 2002; Cook et al., 2004) (Figure 3.7b). We found that the MCM 
complex retrieved from the mixed lysates was enriched for the faster-migrating 
hypophosphorylated Cdt1 relative to hyperphosphorylated Cdt1 and that the total amount of Cdt1  
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Figure 3.7. 
 
Figure 3.7. CDK-mediated hyperphosphorylation of Cdt1 impairs MCM binding.  
(a) Two views of a homology model of the human MCM2-7-Cdt1 complex as described in Pozo 
et al.(Pozo et al., 2018); numbers refer to individual MCM subunits. The disordered linker 
containing phosphorylation sites is hand-drawn connecting the two structured Cdt1 domains 
(MD and CD) in the model. (b) A lysate of nocodazole-arrested (Cdt1 hyperphosphorylated, 
Geminin-expressing) U2OS cells ectopically expressing HA-tagged Cdt1-WT was subjected to 
immunoprecipitation with anti-MCM2 antibody either alone or mixed with lysate from the same 
cells growing asynchronously. Asynchronous cells contain mostly hypophosphorylated Cdt1. 
Input lysates (lanes 1-3) and bound proteins (lanes 4-6) were probed for HA, MCM6 (as a 
marker of the MCM complex), and Geminin; Ponceau S staining serves as a loading control. An 
asterisk indicates light chain IgG from the immunoprecipitation. The results are representative of 
three independent experiments. (c) Asynchronously growing or nocodazole-arrested HEK293T 
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cells ectopically expressing HA-tagged Cdt1-WT or the Cdt1-Cy variant were lysed and 
subjected to immunoprecipitation with anti-MCM2 antibody. Whole cell lysates (lanes 1 - 4) and 
bound proteins (lanes 5 - 10) were probed for HA, MCM6 and Geminin, respectively; Ponceau S 
staining serves as a loading control. The results are representative of two independent 
experiments. 
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bound to MCM was much higher when hypophosphorylated Cdt1 was available (Figure 3.7b, 
compare lanes 5 and 6).  
Furthermore, we compared the MCM binding ability of Cdt1-WT to the Cdt1-Cy variant 
that cannot bind Cyclin A/CDK1 (Figure 3.5b). We transiently transfected 293T cells and then 
immunoprecipitated MCM2 from asynchronously growing cells or from cells arrested in 
nocodazole. As expected in asynchronously growing cells (mostly hypophosphorylated Cdt1), 
there was little difference in MCM binding ability between Cdt1-WT and Cdt1-Cy (Figure 3.7c, 
lanes 6 and 7). In contrast, in nocodazole-arrested cells, Cdt1-Cy bound MCM significantly 
better than did Cdt1-WT (Figure 3.7c, lanes 9 and 10), even in the presence of Geminin (Figure 
3.7c, lanes 3 and 4). In summary, these results suggest that Cdt1 phosphorylation disrupts its 
interaction with MCM complex, and that this disruption contributes to re-replication inhibition in 
G2 and M phases. We note that this is the first example of direct regulation of the Cdt1-MCM 
interaction by post-translational modification. 
Cdt1 dephosphorylation at the M-G1 transition requires PP1 phosphatase activity 
 Our finding that Cdt1 phosphorylation in G2 and M phase inhibits its ability to bind 
MCM suggests that Cdt1 must be dephosphorylated in the subsequent G1 phase to restore its 
normal function. To explore this notion, we first monitored Cdt1 expression and phosphorylation 
in cells progressing from M phase into G1. We released nocodazole-arrested cells and collected 
time points for analysis by immunoblotting (Figure 3.8a). Geminin is a substrate of the 
Anaphase Promoting Complex/Cyclosome (APC/C) (McGarry and Kirschner, 1998), and as 
expected for an APC/C substrate, Geminin was rapidly degraded within 60 minutes of mitotic 
release.  In contrast, Cdt1 was not degraded during the M-G1 transition but rather, was rapidly 
dephosphorylated coincident with Geminin degradation (Figure 3.8a, compare lanes 3 and 4).  
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Figure 3.8. 
 
Figure 3.8. Cdt1 dephosphorylation at the M-G1 transition requires PP1.  
(a) Nocodazole-arrested U2OS cells were released into fresh medium and collected at the 
indicated time points. Endogenous Cdt1 phosphorylation (top) and Geminin (middle) 
degradation were analyzed by immunoblotting; Ponceau S staining and a non-specific band (*) 
serve as loading controls. The results are representative of two independent experiments. (b) 
Nocodazole-arrested U2OS cells were mock treated (lane 1) or treated with 10 µM RO3306 
(CDK1i, lane 2), or treated with both 10 M RO3306 and with 20 nM calyculin A as indicated 
(CalA, lane 3). Endogenous Cdt1 phosphorylation was analyzed by standard or Phos-tag SDS-
PAGE followed by immunoblotting; Ponceau S staining serves as a loading control. The results 
are representative of three independent experiments. (c) Nocodazole-arrested U2OS cells (lane 2) 
were released into fresh medium for 3 hours and mock treated (lane 1) or treated with 20 nM 
calyculin A 30 minutes after release (lane 3). Endogenous Cdt1 or MCM4 phosphorylation and 
total Geminin were detected by immunoblotting; Ponceau S staining serves as a loading control. 
The results are representative of three independent experiments. 
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We next explored which phosphatase is required for Cdt1 dephosphorylation. We first tested 
phosphatase inhibitors for the ability to prevent Cdt1 dephosphorylation after CDK1 inhibition. 
We tested inhibitors of protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A), which 
are responsible for the majority of protein dephosphorylation in cells (Bollen et al., 2010). We 
treated nocodazole-arrested cells with the CDK1 inhibitor to induce Cdt1 dephosphorylation in 
the presence or absence of calyculin A (Cal A) or okadaic acid (OA)(Swingle et al., 2007). Both 
compounds are potent inhibitors of both PP1 and PP2A, but calyculin A is more effective than 
okadaic acid for inhibiting PP1, particularly at the concentrations we tested (Ishihara et al., 1989; 
Yan and Mumby, 1999). We found that calyculin A maintained Cdt1 hyperphosphorylation 
(Figure 3.8b, compare lanes 2 and 3) whereas concentrations of okadaic acid that inhibit PP2A 
but not PP1 did not affect Cdt1 dephosphorylation (Figure 3.9). In addition, we released 
nocodazole-arrested cells into G1 phase for 30 minutes (to initiate mitotic progression) and then 
treated the cells with calyculin A. As a control, we probed for MCM4, a known PP1 substrate 
that is normally dephosphorylated in G1 phase (Hiraga et al., 2014); calyculin A largely 
prevented MCM4 dephosphorylation (Figure 3.8c). PP1 inhibition also largely prevented Cdt1 
dephosphorylation during the mitosis-G1 phase transition without blocking mitotic progression 
as evidenced by Geminin degradation (Figure 3.8c, lanes 2 and 3). These results suggest that 
the PP1 family phosphatase is required for Cdt1 dephosphorylation. By extension, we suggest 
that PP1 activity is required to re-activate Cdt1-MCM binding and origin licensing in G1 phase. 
Discussion 
Cell cycle-dependent Cdt1 phosphorylation 
Mammalian Cdt1 is degraded during S phase, and this degradation is essential to prevent 
re-replication (Nishitani et al., 2001),30,42,. Perhaps counter-intuitively, Cdt1 then accumulates  
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Figure 3.9. 
 
Figure 3.9. Cdt1 dephosphorylation is inhibited by calyculin A (CalA) and high-dose 
okadaic acid (OA). U2OS cells arrested with nocodazole were treated with MG132 followed by 
mock treatment (lanes 2, 3, 5, and 7) or a CDK1 inhibitor treatment (lanes 4, 6, and 8) to induce 
dephosphorylation. Cells were also treated with okadaic acid (OA, lanes 5-8) or with calyculin A 
(CalA lanes 3-4) at the indicated concentrations. Okadaic acid is expected to inhibit PP2A at low 
concentrations and can only inhibit PP1 at high concentrations (Favre et al., 1997). Cells were 
harvested by mitotic shake off, and whole cell lysates were subjected to standard SDS-PAGE 
followed by immunoblotting with HA antibody. A representative of two independent 
experiments is shown. 
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beginning in late S phase (Rizzardi et al., 2015), and by mitosis reaches a level similar to Cdt1 in 
G1 phase (Ballabeni et al., 2004; Coulombe et al., 2013). Despite the potential danger from re-
licensing and re-replicating G2 DNA, these high Cdt1 levels serve two purposes: 1) Cdt1 is 
essential for stable kinetochore-microtubule attachments (Varma et al., 2012), and 2) high levels 
of Cdt1 in mitosis can improve licensing efficiency in the next G1 phase (Ballabeni et al., 2004). 
In this study, we discovered that Cdt1 phosphorylation by Cyclin A/CDK1, a kinase active 
during G2 phase, inhibits Cdt1 licensing activity and contributes to preventing DNA re-
replication while Cdt1 levels are high in G2 and M phase.  
We analyzed a cluster of inhibitory Cyclin A/CDK1 phosphorylation sites that are 
distinct from the only previously-characterized CDK sites at T29 and S31. T29 phosphorylation 
contributes to Cdt1 degradation during S phase by creating a binding site for the SCFSkp2 E3 
ubiquitin ligase. The sites we identified here, S391, T402, T406, S411, and S491, do not induce 
Cdt1 degradation however. In fact, we previously demonstrated that phosphorylation at these 
sites stabilizes, rather than destabilizes Cdt1 (Chandrasekaran et al., 2011). Aside from 
separating the four linker sites from the most C-terminal S491 site in the 5A allele, we did not 
attempt to systematically dissect these “linker” phosphorylation sites, largely because this region 
of Cdt1 is not strongly conserved among vertebrates (Figure 3.1a and Figure 3.2). Most 
vertebrate Cdt1 linker sequences are nonetheless predicted to be similarly disordered, and most 
have at least one candidate CDK phosphorylation site (Figure 3.2). Interestingly, altering two 
additional sites in this region (converting Cdt1-5A to Cdt1-7A) did not exacerbate the re-
replication phenotype suggesting that four phosphorylations are sufficient to achieve maximal 
Cdt1 inhibition. It may be that the four linker sites vary in their relative importance for inhibiting 
human Cdt1 activity, or it may simply be the need for a total amount of phosphorylation in this 
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region regardless of specific position. In that regard, multisite Cdt1 linker phosphorylation may 
resemble other examples of cell cycle-dependent multisite phosphorylation in which the total 
negative charge is more important than the specific phosphorylated position (Koivomagi et al., 
2011). If so, then all four sites in Cdt1 may work additively to achieve maximal inhibition.  
Although we had previously established that stress-activated MAP kinases (p38 and 
JNK) can phosphorylate these inhibitory sites in Cdt1 during a stress response, and both p38 and 
JNK are active during a G2 arrest, we could detect no contribution of stress MAPK activity to 
endogenous Cdt1 phosphorylation during G2 and M phases. The ability of a JNK inhibitor to 
reverse Cdt1 phosphorylation in nocodazole-arrested cells may be attributed to off-target indirect 
effects of the drug on CDK1 activity (Kim et al., 2010). On the other hand, our findings here do 
shed light on the molecular mechanism of stress-induced origin licensing inhibition. We 
postulate that MAPK-mediated Cdt1 hyperphosphorylation at the linker region blocks Cdt1-
MCM binding just as it does in a normal G2 or M phase, even in cells that do not express 
Geminin.  
The nine phosphorylation sites we tested in this study are by no means the only 
phosphorylation sites in human Cdt1. Unbiased phosphoproteomics studies have detected 
phosphorylation at a total of 22 sites, 13 of which are also serine/threonine-proline  sites (Pozo 
and Cook, 2016). In addition to the nine sites included here, Agarwal et al. recently reported that 
Cdt1 is a substrate for Aurora B kinase, and that phosphorylation at eight sites distributed across 
the N-terminal two-thirds of the Cdt1 primary sequence regulates its direct microtubule binding 
activity (Agarwal et al., 2018). In addition, an incompletely-characterized PEST domain that 
restrains Cdt1 licensing activity by influencing chromatin association (but not stability) includes 
other untested candidate CDK sites (Coulombe et al., 2013). Clearly the spectrum of Cdt1 
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biological activities can be determined by combinations of phosphorylations and 
dephosphorylations, and continued in-depth analyses will yield additional insight into Cdt1 
regulation and function. 
Only Cyclin A/CDK1 phosphorylates Cdt1 in G2/M phase 
Cdt1 only binds endogenous Cyclin A and neither Cyclin E nor Cyclin B. As a result, we 
presume that SCFSkp2 targeting for degradation can only happen once Cyclin A accumulates in 
mid-S phase. The fact that endogenous Cyclin E cannot bind Cdt1 means that Cdt1 is both stable 
and active throughout G1 phase even after Cyclin E/CDK2 becomes active in late G1. Cdt1 is 
thus not a substrate for SCFSkp2 until after Cyclin A has accumulated during S phase, but by then, 
most of Cdt1 has already been destroyed at the onset of S phase by CRL4Cdt2-mediated 
replication-coupled destruction (Jin et al., 2006; Sansam et al., 2006; Abbas et al., 2008; 
Coleman et al., 2015). The basis for cyclin specificity is still not fully understood however. A 
hydrophobic patch on cyclins is critical for substrate recognition (Schulman et al., 1998), and 
subtle differences in this sequence may explain why Cdt1 is not a substrate for either Cyclin E or 
Cyclin B. Alternatively, the catalytic CDK1 subunit itself may contribute to substrate specificity 
(Wang et al., 2017).   
Our binding assays indicate that the Cy docking motif is the only CDK binding site in 
Cdt1. Efficient phosphorylation requires simultaneous interaction of the CDK with both the 
substrate phospho-acceptor site(s) and the CDK docking motif (Loog and Morgan, 2005; Cheng 
et al., 2006). We demonstrate here that the Cdt1 docking motif at positions 68-70 is required for 
phosphorylation not only at the previously-investigated T29 position, but also at sites more than 
300 residues towards the C-terminus. This finding prompts us to speculate that in free Cdt1 (i.e. 
not bound to MCM, ORC, or Cdc6), the linker region is relatively close to the N-terminal 
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regulatory domain containing the Cy motif. The structure of the yeast Cdt1-MCM complex 
indicates that when bound to MCM, Cdt1 is in a relatively extended conformation with the linker 
distant from the N-terminal domain (Frigola et al., 2017),(Yuan et al., 2017; Zhai et al., 2017). 
This extended binding surface with multiple MCM contacts supports a role for Cdt1 in 
maintaining the MCM ring in an open state compatible with DNA loading (Frigola et al., 2017).  
Phosphorylation inhibits Cdt1 binding to MCM 
We found that hyperphosphorylated Cdt1 binds MCM poorly relative to 
hypophosphorylated Cdt1. This observation provides a simple mechanism for Cyclin A/CDK1-
mediated phosphorylation to inhibit Cdt1 licensing activity.  Both the Cdt1 N-terminal domain 
and the linker region are predicted to be intrinsically disordered, and the fact that these regions 
were excluded from mammalian Cdt1 fragments subjected to structure determination supports 
that prediction (Lee et al., 2004; Khayrutdinov et al., 2009). The only structure of full-length 
Cdt1 available to date is part of the budding yeast Cdt1-MCM or ORC/Cdc6/Cdt1/MCM 
complexes (Yuan et al., 2017; Zhai et al., 2017), and budding yeast Cdt1 lacks candidate 
phosphorylation sites in the linker region. For this reason, we cannot determine precisely how 
phosphorylation in the linker inhibits MCM binding. We suggest however, that the introduction 
of multiple phosphorylations either induces a large conformational change in Cdt1 that prevents 
it from extending around the side of the MCM ring or alternatively, these phosphorylations may 
directly repel Cdt1 from the MCM surface (Figure 3.7a).  Of additional note the linker 
phosphorylations are not in the Cdt1 domain that is both necessary and sufficient for Geminin 
binding (Lee et al., 2004; Ferenbach et al., 2005). Thus as expected and consistent with previous 
findings (Sugimoto et al., 2004), this mutation does not affect the binding of Cdt1 to Geminin 
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(data not shown), indicating that the contribution of the phosphorylation site mutations to 
induced re-replication is Geminin-independent. 
PP1-dependent Cdt1 dephosphorylation  
Approximately one-third of all eukaryotic proteins may be dephosphorylated by PP1 
(Bollen et al., 2010). PP1 binds some of its substrates directly via a short motif, RVxF, KGILK 
or RKLHY (Wakula et al., 2003; Bollen et al., 2010). Human Cdt1 contains several such 
predicted PP1 binding motifs and thus may be a direct target of PP1. Alternatively, Cdt1 
dephosphorylation may require an adapter to bind PP1 similar to the role of the Rif1 adapter for 
MCM dephosphorylation (Alver et al., 2017). In either case, the fact that hyperphosphorylated 
Cdt1 binds MCM poorly, plus the fact that the levels of Cdt1 do not change from M phase to G1 
(i.e. Cdt1 is not degraded and resynthesized at the M-G1 transition), means that PP1-dependent 
Cdt1 dephosphorylation activates origin licensing. In that regard, dephosphorylation is the first 
example of direct Cdt1 activation, and it complements indirect activation by Geminin 
degradation in M phase.  
A sequential relay of re-replication inhibition mechanisms 
We propose that Cdt1 activity is restricted to G1 through multiple regulatory mechanisms 
during a single cell cycle, but that the relative importance of individual mechanisms changes at 
different times after G1 (Figure 3.10). At the onset of S phase Cdt1 is first subjected to rapid 
replication-coupled destruction via CRL4Cdt2 which targets Cdt1 bound to DNA-loaded PCNA 
(Arias and Walter, 2006). This degradation alone is not sufficient to prevent re-replication 
however, and a contribution from Cyclin A/CDK2 to create a binding site for the SCFSkp2 E3 
ubiquitin ligase is also essential (Nishitani et al., 2006). We suggest that SCFSkp2-targeting 
occurs primarily in mid and late S phase based on the dynamics of Cyclin A accumulation  
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Figure 3.10. 
 
Figure 3.10. Model for Cdt1 regulation through the cell cycle. Cdt1 levels are indicated by the 
dashed blue line whereas Cdt1 licensing activity is indicated by the solid blue line. Geminin 
protein levels are indicated by the dashed pink line. G1 phase: Cdt1 plays an essential role in 
MCM helicase loading. S phase: Cdt1 is first targeted by the CRL4Cdt2 E3 ubiquitin ligase at the 
onset of S phase and then additionally by SCFSkp2 after phosphorylation by Cyclin A/CDK2. 
Geminin accumulates beginning in early S phase. The amount of duplicated DNA at risk of re-
replication is lowest in early S and highest in G2.  Late S and G2 phase:  Cdt1 re-accumulates 
when Geminin is at peak levels. Cyclin A/CDK1 phosphorylates Cdt1, and both Geminin and 
hyperphosphorylation independently interfere with Cdt1-MCM binding. M-G1 transition: 
Protein Phosphatase 1 is required for Cdt1 dephosphorylation to reactivate MCM loading. 
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(Dahmann et al., 1995; Takeda et al., 2005). A reinforcing mechanism for Cdt1 degradation is 
more important in mid and late S phase than in early S phase because the amount of DNA that 
has already been copied increases throughout S phase. Licensing DNA that hasn’t been copied 
yet is presumably benign, but as S phase proceeds, the amount of DNA that has been copied 
already (i.e. the substrate for re-replication) also increases. The Cdt1 inhibitor, Geminin, begins 
to accumulate in early S phase, and its levels increase along with the amount of replicated DNA 
until Geminin is targeted for degradation by the APC/C during mitosis (McGarry and Kirschner, 
1998; Wohlschlegel et al., 2000). Geminin binding to Cdt1 interferes with Cdt1-MCM binding, 
and since Cdt1-MCM binding is essential for MCM loading, Geminin prevents re-licensing 
(Melixetian et al., 2004; Zhu et al., 2004). This inhibition is particularly important once Cdt1 re-
accumulates after S phase is complete; in late S phase the responsibility for restraining Cdt1 is 
passed from the ubiquitin ligases to Geminin and Cyclin A/CDK1. Just as CRL4Cdt2-mediated 
degradation in S phase is not sufficient to fully prevent re-replication, we demonstrated that the 
presence of Geminin alone is not sufficient to inhibit Cdt1 during G2. Cyclin A/CDK1-mediated 
Cdt1 phosphorylation in a linker domain between two MCM binding sites (Pozo et al., 
2018),(Frigola et al., 2017),(Yuan et al., 2017; Zhai et al., 2017) also prevents Cdt1-MCM 
binding. These (and potentially more) mechanisms to restrain Cdt1 activity are also reinforced by 
regulation to inhibit ORC, Cdc6, PR-Set7, and other licensing activators (Nguyen et al., 2001; 
Vaziri et al., 2003; Arias and Walter, 2007; Tardat et al., 2010). Given that there are many 
thousands of potential origins in mammalian genomes, and the consequences of even a small 
amount of re-replication are potentially dire, precise once-and-only-once replication requires that 
Cdt1 be inhibited by at least two mechanisms at all times from G1 through mitosis. 
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Materials and Methods 
Sequence analysis 
A representative selection of vertebrate sequences for comparison was taken from Miller 
et al. (Miller et al., 2007) and Cdt1 protein sequences retrieved from https://www.uniprot.org/. 
For the alignment, Xenopus tropicalis Cdt1 was replaced with Xenopus laevis Cdt1, Tupaia 
belangeri was replaced with Tupaia chinensis, and no Cdt1 sequence for Echinops telfairi 
(tenrec) was available. Full-length sequences were aligned with ClustalW at 
https://www.genome.jp/tools-bin/clustalw using the default settings. Conservation scores were 
determined according to Capra and Singh (Capra and Singh, 2007), and intrinsic disorder 
predicted at https://iupred2a.elte.hu/ (Dosztanyi et al., 2005). Heat maps were generated in 
GraphPad Prism. 
Cell Culture and Manipulations 
U2OS Flp-in Trex cells (Malecki et al., 2006) bearing a single FRT site (gift of J. Aster) 
and HEK 293T cells were cultured at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% (v/v) fetal bovine serum, 2 mM L-glutamine, 10 U/mL of 
penicillin and 10 µg/mL of streptomycin. For kinase inhibitor treatments, cells arrested by 
thymidine-nocodazole synchronization were incubated with each inhibitor combination for 1 
hour or 15 minutes and harvested by mitotic shake-off as described (Chandrasekaran et al., 
2011).  Cells were treated with 10 μM, RO-3306 (Sigma), 6 μM CVT313 (Sigma), 10 μM JNK 
inhibitor VIII (Sigma), 30 μM SB203580 (Sigma) or 20 nM, calyculin A (LC Laboratories) as 
indicated. For the transient expression of Cdt1 variants, HEK 293T cells were transfected with 
Cdt1 expression plasmids using PEI Max (Sigma). Transfected cells were harvested after 16 
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hours and processed for subsequent co-immunoprecipitation assays. All cell lines were validated 
by STR profiling and mycoplasma test.  
Antibodies 
Antibodies were purchased from the following sources: Cdt1 (Cat# 8064), Chk1 (Cat# 
2345), phospho-Chk1 S345 (Cat# 2341), Cyclin E1 (Cat#4129), MAPKAPK-2 (Cat#), Phospho-
MAPKAPK-2 T334 (Cat#3007), phospho-Histone H2A.X Ser139 (Cat#9718) from Cell 
Signaling Technologies; hemagglutinin (HA) (Cat#11867423001) from Roche; Geminin 
(Cat#sc-13015), Cdc6 (Cat#sc-9964), MCM6 (Cat#sc-9843), Cyclin A (Cat#sc-596), Cyclin B1 
(Cat#sc-245) and CDK2 (Cat#sc-163) from Santa Cruz Biotechnology; MCM4 (Cat#3728) from 
Abcam. MCM2 antibody (Cat#A300-191A) used for co-immunoprecipitation experiment was 
purchased from Bethyl Laboratories. Serum to detect CDK1 was a gift from Y. Xiong 
(University of North Carolina), and MPM2 antibody was a gift from R. Duronio (White et al., 
2011) (University of North Carolina). Alexa 647-azide used in flow cytometry analyses was 
purchased from Life Technologies, and secondary antibodies for immunoblotting were 
purchased from Jackson ImmunoResearch. 
Flow cytometry 
U2OS cells were cultured in complete medium with 1 μg/mL doxycycline for 48 hours to 
induce expression of wild type or mutant Cdt1. Cells were labeled with EdU (Sigma) using a 
final concentration of 10 μM in the medium for 1 hour followed by trypsinization. The cells were 
fixed with 4% formaldehyde (PFA) for 15 minutes, extracted with 0.5% Triton X-100 for 15 
minutes, then processed for EdU detection by conjugation to Alexa Fluor 647 azide in 1 mM 
CuSO4 and 100 mM ascorbic acid; DNA was stained with 1 µg/mL DAPI (Life Technologies) in 
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100 µg/mL RNAse A (Sigma). Samples were analyzed using a Beckman Coulter CyAn ADP 
cytometer and Summit software 4.3. 
Protein-protein interaction assays 
For polyhistidine pulldown assays, cells were lysed in lysis buffer (50 mM HEPES pH 
8.0, 33 mM KAc, 117 mM NaCl, 20 mM imidazole, 0.5% triton X-100, 10% glycerol) plus 
protease inhibitors (0.1 mM AEBSF, 10 µg/mL pepstatin A, 10 µg/mL leupeptin, 10 µg/mL 
aprotinin), phosphatase inhibitors (5 µg/mL phosvitin, 1 mM β-glycerol phosphate, 1 mM Na-
orthovanadate), 1 mM ATP, 1 mM MgCl2, 5 mM CaCl2 and 15 units of S7 micrococcal nuclease 
(Roche). Lysates were sonicated for 10 seconds at low power followed by incubation on ice for 
30 minutes and clarification by centrifugation at 13,000 x g for 15 minutes at 4°C. The 
supernatants were incubated with nickel NTA agarose beads (Qiagen) for 2 hours at 4°C with 
rotation. Beads were rinsed 4 times rapidly with ice-cold lysis buffer followed by boiling in SDS 
sample buffer for 5 minutes prior to immunoblot. 
For co-immunoprecipitation assays, cells were lysed in Co-IP buffer (50 mM HEPES pH 
7.2, 33 mM KAc, 1 mM MgCl2, 0.5% triton X-100, and 10% glycerol) containing protease 
inhibitors (0.1 mM AEBSF, 10 µg/mL pepstatin A, 10 µg/mL leupeptin, 10 g/mL aprotinin), 
phosphatase inhibitors (5 µg/mL phosvitin, 1 mM β-glycerol phosphate, 1 mM Na-
orthovanadate), 1 mM ATP, and supplemented with 5 mM CaCl2 and 15 units of S7 micrococcal 
nuclease (Roche). Lysates were sonicated for 10 seconds at low power followed by incubation 
on ice for 30 minutes and clarification by centrifugation at 13,000 x g for 15 minutes at 4°C. The 
supernatants were incubated and rotated with Protein A beads (Roche) with an anti-Mcm2 
antibody (Bethyl, 1:1000) at 4°C with rotation for 4 hours. Beads were rinsed three times with 
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ice-cold co-IP buffer then eluted by boiling in sample buffer for subsequent immunoblot 
analysis. 
Immunofluorescence microscopy 
U2OS cells cultured on cover glass were fixed with 4% PFA for 15 minutes and 
permeabilized with 0.5% Triton in PBS for 5 minutes. Cells were blocked in 1% BSA for 30 
minutes followed by incubation with primary antibody overnight at 4°C and secondary antibody 
for 1 hour at room temperature. Cells were stained with 1 μg/ml DAPI for 5 minutes before 
mounting with the ProLong® Gold Antifade mounting medium (life technologies). Fluorescent 
images were captured on a Nikon 2000E microscope. The areas of nuclei were measured by 
using the Adobe Photoshop software. 
Statistical analysis 
 The differences were considered significant with a p-value less than 0.05 in an unpaired 
Student t-test or a Mann–Whitney U -test using Sigmaplot software (Systat Software). 
 
 
 
 
 
 
 
 
 
 
107 
 
 
CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
Introduction 
 During the course of this study we discovered new aspects of Cdt1 function and 
regulation with respect to origin licensing. In particular, using the hypomorphic variants we 
showed the need for multiple Cdt1-MCM interactions for efficient origin licensing and 
extrapolated these results to structural insights into human Cdt1-MCM interactions. Also, using 
the hypermorphic variant, we discovered a new mechanism of Cdt1 regulation involving Cyclin 
A which relies on restraining Cdt1 activity independently from the known phosphodegron-
mediated regulation of Cdt1 protein stability. Although we made significant headway in 
describing and understanding this new phenomena, many questions still remain. The remainder 
of this chapter focuses on questions in the field that need to be addressed based on the 
discoveries presented here and in Cdt1 biology in general. 
The unexpected Cyclin A-dependent regulation of Cdt1 in addition to generating a 
phosphodegron. 
 Research in our lab has shown that Cyclin A/Cdk1-dependent phosphorylation of the 
linker region of Cdt1 is important to inhibit origin licensing and thus DNA re-replication. How 
does phosphorylation of the linker region in Cdt1 act to negatively regulate Cdt1 function? Many 
proteins are regulated by PTMs, including phosphorylation, and this regulation can involve 
changes in overall protein conformation (Nussinov et al., 2012). In the case of Cdt1, 
phosphorylation by Cyclin A/Cdk1 could lead to a conformational change unconducive to the 
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Cdt1-MCM interactions required for origin licensing. In line with this idea, our lab has 
previously shown that phosphorylating Cdt1 in the linker region by p38 and JNK during a stress 
response resulted in inhibition of MCM loading as well as protection from ubiquitin-mediated 
proteolysis (Chandrasekaran et al., 2011). However, the residues targeted for phosphorylation 
and the CRL4Cdt2 recognition motif are in almost opposite extremes of the protein, suggesting the 
possibility of global conformational changes in Cdt1. This idea can be tested in vitro by 
expressing Cdt1 protein versions with and without phosphorylated linkers, i.e. phosphomimetics 
and unphosphorylatable variants, and biochemically and biophysically asking whether these 
mutational alterations change Cdt1 structure. On the other hand, the phosphorylation events in 
the linker region of Cdt1 can cause not a global conformation change but rather propagate to 
regions of Cdt1 important for Cdt1-MCM interactions. In this scenario, the global protein 
conformation could remain the same but domains required for origin licensing (the middle and/or 
C-terminal domain) are altered and/or positioned in such a way to inefficiently engage the MCM 
complex. 
 It is possible that decorating the linker region with PTMs serves to recruit other protein 
factors that collectively inhibit Cdt1-MCM interactions. It is well known that phosphorylation 
events act as priming events for either more PTMs or for the recruitment of other protein factors 
to a protein (Cesaro and Pinna, 2015; Miller and Turk, 2018). One can test this idea by using an 
IP-mass spec approach. Presumably the mutationally altered Cdt1 variant could interact with a 
different set of protein factors than WT Cdt1. These ideas are not mutually-exclusive as PTMs 
can alter protein conformation while at the same time exposing protein-protein interacting 
interfaces, thus potentially inhibiting and recruiting protein inhibitors to Cdt1 concurrently.  
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How does Geminin really influence Cdt1 activity in origin licensing? 
 Crystal structures of the middle domain of Cdt1 in complex with Geminin are available 
(Lee et al., 2004) and although our results (see Chapter 2) support a model where Geminin 
inhibits a newly defined Cdt1-MCM binding domain, other studies suggest Geminin is also 
needed for origin licensing (De Marco et al., 2009). That is, Geminin is both an “activator” of 
origin licensing in G1 and subsequently an inhibitor of origin licensing in S and G2/M phase (De 
Marco et al., 2009). De Marco et al. discovered a quaternary structure between Cdt1 and 
Geminin and suggested that this complex can be permissive at low Geminin concentrations and 
inhibitory at higher Geminin concentrations (De Marco et al., 2009). Although this idea fits well 
with Geminin levels throughout the cell cycle where Geminin levels are low during G1 
(permissive), increase at the G1/S boundary, and continually increase into G2/M (inhibitory), 
more investigation in needed, particularly since Geminin levels in G1 are virtually undetectable 
in recent live-cell imaging analyses conducted in our lab and others (Grant et al., 2018) (Sakaue-
Sawano et al., 2017). How does the Cdt1:Geminin stoichiometry result in a molecular switch 
between a permissive vs inhibitory complex for origin licensing? One can address this question 
by first determining the physiological protein concentration of Geminin in G1 and then use 
established in vitro origin licensing reconstitution assays in Xenopus egg extract using various 
stoichiometric Cdt1:Geminin ratios. 
 During the course of this study, we found that the middle domain of Cdt1 is required for 
efficient Cdt1-MCM interactions (Pozo et al., 2018), and this domain is also the Cdt1-Geminin 
interaction region (Lee et al., 2004). Is Geminin exerting its origin licensing inhibitory role by 
blocking Cdt1-MCM interactions through Cdt1’s middle domain? A way to test the idea that 
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Geminin is inhibiting this new Cdt1-MCM binding domain, which is different from the 
previously defined MCM binding domain, can be to first express fragments of Cdt1 
corresponding to the middle domain (new MCM binding domain) and the previously known 
MCM binding domain (C-terminus). Next, in vitro interaction assays can be carried out where 
the middle and C-terminal fragments are mixed with cell lysates in addition to exogenous 
Geminin. If indeed the middle domain of Cdt1 is where Geminin exerts its inhibitory function, 
then only the middle fragment of Cdt1 will show decreased interaction with MCM. On the other 
hand, the C-terminus fragment will have near normal interaction with MCM as compared to full 
length Cdt1. This result would yield mechanistic insight into the inhibitory role of Geminin in 
origin licensing and further support the existence of an additional Cdt1-MCM binding domain.   
How do perturbations in origin licensing lead to developmental disorders or cancer? 
 The precise control of origin licensing is essential for normal cell proliferation. In 
humans, Cdt1 is the licensing factor that is subjected to the most regulation. It is not surprisingly 
then, that changes in Cdt1 regulation and activity result in developmental problems and 
oncogenesis (Arentson et al., 2002). For instance, the naturally-occurring mutations used in this 
study are found in patients suffering from a form of dwarfism called Meier-Gorlin syndrome 
(Bicknell et al., 2011a; de Munnik et al., 2012). This developmental disorder begins in utero and 
continues throughout adolescence. From our results we infer that the hypomorphic mutations 
actually lengthen the cell cycle by slowing down G1 progression, while the hypermorphic 
mutation leads to genome instability. Both of these scenarios result in cell proliferation defects 
that over time can result in developmental disorders.  
 On the other hand, Cdt1 overexpression is observed in many types of cancer (Fujita, 
2006). The current thinking is that cells cannot regulate Cdt1 activity when overexpressed and 
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thus Cdt1 can re-license origins and induce a DNA re-replication phenomenon. This process in 
turn results in genome instability and potentially oncogenesis (Fujita, 2006; Liontos et al., 2007; 
Petropoulou et al., 2008).  
How and why did Cdt1 evolve to have a secondary role in mitosis?  
 Many proteins have more than one function in cells and Cdt1 is no exception. A role of 
Cdt1 in mitosis was discovered in our lab. Cdt1 is required for robust kinetochore-microtubule 
attachment during chromosome segregation in mitosis (Varma et al., 2012). Depleting Cdt1 in 
cells specifically during G2/M and after its licensing role in G1 results in mitotic cells arresting 
at prometaphase (Varma et al., 2012). We currently know that Cdt1 interacts with the Hec1 loop 
of the Ndc80 complex at the kinetochore-microtubule interface, and that this interaction 
maintains the Hec1 subunit in an extended conformation (Varma et al., 2012). In addition, a 
recent study showed that Cdt1 directly binds microtubules and mapped the microtubule-binding 
regions to the middle and C-terminal domains of Cdt1 (Agarwal et al., 2018). Furthermore, 
Agarwal et al. showed that the mitotic kinase Aurora B interacts with and phosphorylates Cdt1 to 
stabilize kinetochore-microtubule attachments (Agarwal et al., 2018). These studies have 
increased our knowledge of Cdt1 function during mitosis. However, this novel role for Cdt1 
remains largely unexplored and it would be interesting to dissect the molecular mechanism of 
why the PTMs on Cdt1 at the G2/M boundary are necessary for its mitotic function.  
 It is interesting to consider that Cdt1 interacts with both the MCM complex and the Hec1 
loop providing the correct “brace” to either keep the MCM ring open or to maintain the Hec1 
subunit in its extended conformation. It appears as though Cdt1 has evolved in cells to maintain 
protein complexes in the right conformation to achieve their function. Furthermore, because of 
its mitotic role, it makes sense for cells to increase Cdt1 stability at the G2/M boundary while at 
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the same time preventing its licensing activity. It would be interesting to know what PTMs are 
found in Cdt1 during its mitosis role. One way to detangle the posttranslational modification 
required for Cdt1 function at each cell cycle phase can be to carry out an IP mass spec approach 
from synchronized cells. What function for Cdt1 came first, origin licensing or kinetochore-
microtubule attachment remains unclear.  
 The cell cycle is a very complex biological process essential for all living things. By 
focusing on single key events of the cell cycle, we can begin to understand how the cell cycle 
machinery controls cell proliferation throughout normal development and also during disease 
states. In this work, we focused on the process of origin licensing with emphasis on the function 
and regulation of the Cdt1 protein. Using naturally-occurring and engineered mutations in Cdt1, 
we made progress towards having a deep understanding of the molecular mechanisms controlling 
origin licensing and how this event is regulated throughout the cell cycle. Ultimately, studying in 
detail the various events of the cell cycle will lead to a more well-rounded and precise 
understanding of the molecular mechanism behind this fundamental process. 
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